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ABSTRACT 
Adolescence and young adulthood are periods when several mental 
disorders, such as mood, anxiety, psychotic and substance use disorders, are 
diagnosed for the first time. In the treatment of these disorders among young 
people, the use psychotropic medications has become more common during 
the last two decades, but rather little is known about who uses these 
medications. There is also a lack of population-based studies from childhood 
to adulthood that have studied the psychopathology predictors of psychiatric 
hospital treatment. The scarcity of studies is mainly explained by the fact that 
psychiatric hospital treatment is a rare event. However, psychiatric hospital 
treatment is an indicator of severe psychiatric disorder and knowing its 
predictors is therefore important. 
It has previously been shown that, among individuals with mental 
problems, the first psychiatric treatment contact often occurs in late 
adolescence or young adulthood. However, the onset of symptoms has often 
occurred several years before, in childhood. Early identification of 
individuals who later develop psychiatric problems requiring psychotropic 
medication and psychiatric hospital treatment has implications for 
prevention. The aims of this thesis are to describe the cumulative incidence 
of psychotropic medication use from age 12 to age 25, and to study factors at 
age eight that predict psychotropic medication use and psychiatric hospital 
treatment between age 12 and 25. 
The thesis is part of the multicentre Finnish Nationwide 1981 Birth 
Cohort Study, which has been conducted at all five university departments of 
child psychiatry in Finland. A representative random sample of all children 
born in 1981 and alive at age eight in 1989 was primarily selected in 1989 
(6,017 of 60,007; 10%). At age eight, 5,813 children were assessed using 
questionnaires (97% of 6,017). The parents and the teacher completed 
questionnaires with items concerning family structure, parental education 
level, conduct problems, hyperactive problems, emotional symptoms, 
bullying, and victimization of bullying behavior. The children themselves 
completed the Children’s Depression Inventory with questions regarding 
depressive symptoms, and extra questions regarding bullying, and 
victimization of bullying behavior. Between 1994 and 2005, when the 
participants were 12-13 to 24-25 years old, the personal identification 
numbers of 5,525 subjects (92% of 6,017) were linked to the nationwide Drug 
Prescription Register and the nationwide Finnish Hospital Discharge 
Register. Information about psychotropic medication use and psychiatric 
hospital treatment between age 12 and 25 was collected from these registers. 
The main results in the thesis are that more than every seventh subject 
had used psychotropic medications by age 25, and that psychotropic 
medication use and psychiatric hospital treatment are strongly associated 
Abstract 
 10
with psychiatric symptoms at age eight. Some of the associations between 
childhood and adulthood were very similar among males and females, such 
as depressive symptoms predicting treatment of depressive disorders and 
non-intact family structure predicting a wide range of different psychiatric 
treatments. However, the predictive value of several characteristics at age 
eight were different among males and females. Among males, particularly 
acting-out behaviors, while among females, especially depressive and anxiety 
symptoms and being a victim of bullying behavior predicted antipsychotic 
use, antidepressant use, and psychiatric hospital treatment by age 25. 
The findings that 15% had purchased any psychotropic medication and 
12% had purchased antidepressants between age 12 and 25 extend previous 
reports of one-year prevalence. The study shows that a considerable 
proportion of the population has used psychotropic medication at some point 
by age 25. The results of strong predictive associations between psychiatric 
problems at age eight and psychotropic medication use and psychiatric 
hospital treatment by age 25 are in line with prior population-based 
prospective studies. However, the novel result that the psychiatric outcomes 
are partly predicted differently among males versus females, should be 
further studied using large population-based cohorts. If the results are 
replicated and screening of mental health problems is implemented in 
primary schools, sex-specific screening strategies might be warranted. 
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TIIVISTELMÄ (ABSTRACT IN FINNISH) 
Monet mielenterveyden häiriöt, kuten mielialahäiriö, ahdistuneisuushäiriö, 
psykoottinen häiriö ja päihdehäiriö, todetaan usein ensimmäistä kertaa 
nuoruudessa tai varhaisaikuisuudessa. Kahden viimeisen vuosikymmenen 
aikana nuorten mielenterveyshäiriöiden hoidossa on käytetty lisääntyvästi 
psyykelääkkeitä, mutta tietoa siitä, ketkä lääkkeitä käyttävät, on varsin 
vähän. Lisäksi vain harvoissa väestöpohjaisissa, lapsuudesta aikuisuuteen 
ulottuvissa tutkimuksissa on selvitetty psykiatrista sairaalahoitoa ennustavia 
mielenterveyteen liittyviä tekijöitä. Tutkimusten vähäisyys selittyy pääosin 
psykiatristen sairaalahoitojaksojen harvinaisuudella. Koska psykiatrinen 
sairaalahoito on merkki vakavasta psykiatrisesta häiriöstä, on sen 
ennustetekijöiden tunteminen kuitenkin tärkeää. 
Aikaisemmissa tutkimuksissa on osoitettu, että mielenterveysongelmista 
kärsivät henkilöt käyttävät psykiatrisia palveluita ensimmäistä kertaa usein 
myöhäisnuoruudessa tai varhaisaikuisuudessa. Ensimmäiset oireet ovat 
kuitenkin puhjenneet usein jo vuosia aikaisemmin. Ennaltaehkäisyn 
kannalta on tärkeä tunnistaa varhaisessa vaiheessa henkilöitä, joilla on 
kohonnut riski myöhempiin, psyykelääkitystä tai psykiatrista sairaalahoitoa 
vaativiin mielenterveysongelmiin. Tämän väitöskirjan tarkoituksena on 
selvittää psyykelääkkeiden käytön kumulatiivista ilmaantuvuutta 12–25 –
vuotiailla ja selvittää kahdeksan vuoden iässä arvioituja tekijöitä, jotka 
ennustavat psyykelääkkeiden käyttöä ja psykiatrista sairaalahoitoa 12–25 
vuoden iässä. 
Väitöskirja on osa Finnish Nationwide 1981 Birth Cohort -
monikeskustutkimusta, jonka toteuttamiseen osallistuivat Suomen kaikki 
viisi lastenpsykiatrista yliopistoyksikköä. Kaikista vuonna 1981 syntyneistä ja 
vuonna 1989 kahdeksan vuoden iässä elossa olleista lapsista poimittiin 
vuonna 1989 edustava otos (6017 lasta eli noin 10 % kaikista 60 007 
lapsesta). Kahdeksan vuoden iässä tietoja kerättiin kyselylomakkeiden avulla 
5817 lapsesta (97 % 6017 lapsesta). Lasten vanhemmat ja opettajat vastasivat 
kysymyksiin, jotka koskivat perherakennetta, vanhempien koulutustasoa, 
lapsen käytösongelmia, ylivilkkauteen liittyviä ongelmia, tunne-elämän 
ongelmia sekä kiusaamista tai kiusaamisen uhriksi joutumista. Lapset itse 
täyttivät Children’s Depression Inventory -kyselylomakkeen, joka sisältää 
kysymyksiä masennusoireista. Lisäksi he vastasivat kiusaamista ja 
kiusaamisen uhriksi joutumista koskeviin kysymyksiin. Seurantavaiheessa 
5525 henkilön (92 % 6017 lapsesta) henkilötunnus yhdistettiin 
valtakunnallisista lääkekorvaus- ja hoitoilmoitusrekistereistä vuosina 1994–
2005 kerättyihin tietoihin psyykelääkkeiden ja psykiatrisen sairaalahoidon 
käytöstä ikävuosina 12–25. 
Tiivistelmä (abstract in Finnish) 
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Väitöskirjatutkimuksen päätulokset osoittivat, että 25 vuoden ikään 
mennessä useampi kuin joka seitsemäs henkilö on käyttänyt psyykelääkitystä 
ja että psyykelääkkeiden käyttö ja psykiatrinen sairaalahoito ovat yhteydessä 
kahdeksan vuoden iässä ilmoitettuihin psyykkisiin oireisiin. Lapsuusiän 
ennustekijät olivat miehillä ja naisilla joissakin tapauksissa samoja. 
Molemmilla sukupuolilla masennusoireet olivat yhteydessä myöhempään 
masennuksen hoitoon ja rikkonainen perherakenne oli yhteydessä moniin 
erilaisiin psykiatrisiin hoitoihin.  Monien tekijöiden ennusarvo oli miehillä ja 
naisilla kuitenkin erilainen. Miehillä varsinkin käytösongelmat ennusti 
antipsykoottisten lääkkeiden ja masennuslääkkeiden käyttöä sekä 
psykiatrista sairaalahoitoa ennen 25 vuoden ikää. Naisilla näiden hoitojen 
saamista ennustivat erityisesti lapsuusiän masennusoireet, 
ahdistuneisuusoireet ja kiusatuksi tuleminen. 
Aiempien tutkimusten tuloksia psyykelääkekäytön yhden vuoden 
vallitsevuudesta laajentaa väitöskirjatutkimuksen löydös, jonka mukaan 15 % 
tutkituista oli ostanut ennen 25 vuoden ikää jotain psyykelääkettä, ja 12 % oli 
ostanut masennuslääkkeitä. Tämä väitöskirja osoittaa, että huomattava osa 
väestöstä on käyttänyt psyykelääkkeitä 25 vuoden ikään mennessä. 
Lapsuusiän psyykkisten oireiden ja myöhemmän psyykelääkkeiden käytön 
sekä psykiatrisen sairaalahoidon välillä havaitut vahvat yhteydet ovat 
yhdenmukaisia aiempien väestöpohjaisten pitkittäistutkimusten tulosten 
kanssa. Nyt havaittua ilmiötä, jonka mukaan lapsuusiän psyykkiset oireet 
ovat miehillä ja naisilla eri tavoin yhteydessä psykiatriseen hoitoon 
nuoruudessa ja varhaisaikuisuudessa, pitäisi tarkastella myös muissa 
laajoissa väestöpohjaisissa pitkittäistutkimuksissa. Mikäli tulokset ovat 
toistettavissa ja peruskoulun ensimmäisten luokkien oppilaille kehitetään 
mielenterveysongelmien seulontajärjestelmä, pitäisi tytöillä ja pojilla 
mahdollisesti käyttää erilaisia kriteereitä. 
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1 INTRODUCTION 
Mental health refers to mental or psychological well-being and is more than 
the absence of mental disorders, according to the definition by the World 
Health Organization (WHO) (241). Mental disorders are behavioral or 
psychological syndromes that are associated with distress or disability (14). 
Among persons with mental disorders, adolescence and young adulthood are 
the periods when several mental disorders are treated for the first time (129). 
Common mental disorders during adolescence and young adulthood include 
mood, anxiety, psychotic and substance use disorders (61, 66). Treatment of 
mental disorders during adolescence and young adulthood can be 
pharmacological and non-pharmacological, including, e.g. psychosocial 
interventions, supportive therapy, and psychotherapy. The treatment is often 
provided as outpatient treatment, but in some cases also as inpatient 
treatment, i.e. as psychiatric hospital treatment (PHT). Still, the majority of 
children and young people with mental health problems do not have a 
treatment contact (10, 99, 129, 213, 219). 
There have been certain changes in the treatment of mental disorders 
among adolescents and young people. For example, since the beginning of 
the 1990s, the use of psychotropic medication among young people has 
increased in many high-income countries (170, 234, 250). In Finland, there has 
also been an increase in the one-year prevalence of psychiatric hospital 
treatment (PHT) among adolescents (232), which is in contrast to, e.g., the 
USA (152).  
Though the psychiatric treatment often starts in late adolescence or young 
adulthood (129), mental health problems or deviant behavior can often be 
found years before, in childhood, among young adults with mental health 
problems  (49, 104, 218). The identification of early symptoms makes targeted 
early interventions possible, which may in turn reduce and prevent 
psychiatric disorders and related events (165). The principle of early 
interventions has also shown utility from an economic point of view. For 
example, James J. Heckman, who won the Nobel Prize in Economic Sciences 
in 2000, has demonstrated that the ratio of invested money per later 
benefited money is highest for young disadvantaged children (101, 102). 
The first years of school provide several advantages for identifying 
children at risk of adverse outcomes. First, in Western countries, almost all 
children attend school, i.e. the identification program can reach almost every 
child. Second, patterns of behavior and social interaction of a whole group of 
children can be observed by the teachers. Third, once the children have 
learnt to read and write, standardized questionnaires addressed to the 
children themselves can be implemented. Fourth, the identification occurs 
before puberty, i.e. before many problems are serious enough to fulfil 
diagnostic criteria. Thus, it is possible to identify many subclinical symptoms 
Introduction 
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in an age group that is rather homogenous with respect to hormonal factors 
and other developmental aspects of adolescence.  
There is a scarcity of detailed information about which factors in early 
school years predict different outcomes in adulthood. For example, there is 
little information about what predicts phenomena that have recently become 
more common, such as psychotropic medication use, and rare events, such as 
PHT. Furthermore, does psychopathology in childhood among males versus 
females predict outcomes in adulthood differently? This scarcity of 
information is understandable, since longitudinal studies from childhood to 
adulthood have only recently emerged (55, 61, 82, 86, 132, 194). Most of the cohorts 
have not included over 1,500 subjects, making rare events and interactions 
difficult to study. However, such detailed information is of importance when 
planning large-scaled preventive interventions. It is of note that several 
ethical criteria also need to be fulfilled when systematic identification or 
screening of risk symptoms and behaviors among children is applied. These 
issues are, e.g., the availability of effective and cost-effective treatment and 
that the screening procedure is acceptable to the population and does not 
cause labeling (165). In sum, all these issues related to screening and 
prevention remain highly relevant, because mental disorders cause the 
highest disability rates among young adults (161), are the major causes of 
death among young people (217), and contribute to very high costs for the 
society (64).   
This thesis is part of the Finnish Nationwide 1981 Birth Cohort Study 
(FN1981BCS). The focus is on patterns of psychopharmacological treatment 
and inpatient treatment, because of the increased use of psychotropic 
medication (172, 234, 250) and because of the severe disorders associated with 
psychiatric hospital treatment (37). Because there is a scarcity of longitudinal 
studies of psychotropic medication use, more emphasis is put on 
psychotropic medication use than on hospital treatment of psychiatric 
disorders. The major aim is to study childhood predictors of psychotropic 
drug use and psychiatric hospital treatment.  
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2 REVIEW OF THE LITERATURE 
2.1 PSYCHIATRIC TREATMENT DURING 
ADOLESCENCE AND YOUNG ADULTHOOD 
The time of onset of most psychiatric disorders is childhood or adolescence 
(61, 179). However, only a minority of children and young persons with mental 
problems receive any psychiatric treatment (10, 21, 99, 129, 213, 219). Help-seeking 
among adolescents is often delayed: the time from the onset of the disorder 
to the first treatment contact tends to be several years (129).  
2.1.1 MEASUREMENT OF PSYCHIATRIC TREATMENT 
Information about treatment is obtained by asking the person via a 
questionnaire or an interview, or from official records, such as medical 
records or administrative registers. Questionnaires or interviews addressed 
to the patient are not necessarily reliable concerning the age at which the 
treatment has been given (33). Administrative registers provide a more exact 
measurement of the timing of the treatment. However, registers covering the 
total population regardless of insurance status or place of residence exist only 
in the Nordic countries (5, 93).  
2.1.2 PSYCHOTROPIC MEDICATION USE 
The use of psychotropic medication among adolescents and young adults has 
increased in several western countries during the last two decades (172, 234, 250). 
In the USA and several European countries especially the use of 
antidepressants, antipsychotics and stimulants has increased. However, in 
Finland, the use of stimulants has remained low (251). Therefore, the focus will 
be on antipsychotics and antidepressants. 
2.1.2.1 Antipsychotics 
Antipsychotics are a group of psychotropic medications mainly aiming to 
reduce psychotic symptoms, such as hallucinations, delusions, and paranoid 
thoughts in schizophrenia and related disorders. However, some 
antipsychotic medications are also used as mood stabilizers in bipolar 
disorder (160, 170) and unstable personality disorder (245); as aggression-
reducing medication in conduct disorder (4, 12, 111) and autism spectrum 
disorders (111); as adjunctive medication in psychotic depression; and off-label 
for anxiety (77) and sleeping problems (242).  
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Antipsychotics are divided into first-generation or typical antipsychotics 
and second-generation or atypical antipsychotics, depending on when they 
were developed. Since the introduction of second-generation antipsychotics, 
the use of antipsychotics has increased in most Western countries. In 
Finland, the one-year prevalence of antipsychotic use in 2007 was 0.4% in 
the age group 11-15, 0.7% in the age group 16-20, and 0.9% in the age group 
21-26 (25). Antipsychotic use has increased especially among children and 
adolescents in many countries (77, 170, 234). The increased prevalence rate has 
also been affected by the fact that the length of treatment periods with 
antipsychotics has become longer; not only the number of new users per year 
has increased (119, 121, 193). In addition, the wide range of conditions for which 
antipsychotics are used (12, 77, 111, 160, 170, 234, 242) may have affected the increased 
use of antipsychotics.  
Reports based on data from the USA (73, 248), Canada (4) and the 
Netherlands (119, 248) have reported higher antipsychotic prevalence among 
males than females, while reports from German (248) and Finnish (25) data 
have reported similar estimates for the sexes. In Finland, the use of 
antipsychotics is lower among children than among adults (25). However, in 
the Netherlands in 2005 (119) and in the USA in 2001 (73, 178), the one-year 
prevalence of antipsychotic use in the age group 10-14 years was higher or 
similar to that in the age group 15-19 years. There are only a few studies 
reporting the annual incidence of antipsychotic use among young people (53, 
60, 193, 204, 250), but there are no previous reports of the cumulative incidence 
using a nationwide cohort from early adolescence to young adulthood. 
2.1.2.2 Antidepressants 
Antidepressants are a group of psychotropic medications aiming to reduce 
depressive symptoms. In addition, many antidepressants have also been 
found useful in the treatment of, e.g. panic disorder (15), social phobia (28), 
post-traumatic stress disorder (28), obsessive-compulsive disorder (17), and 
eating disorders (16).  
The newer antidepressants are mostly well tolerated, which has possibly 
resulted in a lower threshold for physicians to prescribe antidepressants for a 
variety of conditions (173). This may be one reason why the use of 
antidepressants has become common among young people. Other possible 
explanations for the increased antidepressant use include the possible 
increase in depression prevalence (58), the lowered threshold of help-seeking 
(182), and the wide range of disorders for which antidepressants are 
recommended (15-17, 28). In Finland, from 1997 to 2007, the one-year 
prevalence of antidepressant use in the age group 21-26 has almost tripled to 
6% (25). Antidepressants are the most frequently prescribed psychotropic 
medication in Finland (122) and in the USA (172, 182).  
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Females use antidepressants more often than males in late adolescence 
and young adulthood, according to reports from Finland (25), Germany (249), 
Denmark (249) and the Netherlands (249), while the prevalence is similar in the 
sexes in the USA (249). Among children and adolescents younger than 15 
years,, the use of antidepressants is more common in the USA than in 
Finland (25), Germany (249), Denmark (249) and the Netherlands (249). Among 
young adults, the prevalence of antidepressants is rather similar in Finland 
(25) and the USA (158, 172, 249). Some studies have reported the annual incidence 
of antidepressant use among young people (24, 53, 60, 204, 250), but currently 
there is only one other report of the cumulative incidence using a nationwide 
cohort from early adolescence to young adulthood (24). 
2.1.2.3 Polypharmacy 
The term polypharmacy is in many studies defined as the use of two or more 
medications together (57, 159). However, several other terms have been used to 
describe similar medication utilization patterns: co-medication (84, 229), 
multiple use (79, 153, 188), concomitant use (203, 250), and concurrent medication 
(229). Thus, the classification of polypharmacy has varied considerably across 
studies (229). First, many define polypharmacy as using two or more 
medications from different medication classes, e.g. using antidepressants 
and benzodiazepines together. This has been referred to as across-class 
polypharmacy (159) or multiclass psychotropic treatment (57). The use of two 
different medications from the same class, e.g. two antipsychotics, has been 
referred to as within-class polypharmacy (159). Second, some have measured 
concomitant use of several medications by reporting point prevalence 
estimates (247), e.g. surveys of physician visits including several prescriptions 
(57, 92, 159). Others have measured multiple use of several medications by 
reporting period prevalence estimates (247), meaning that two different 
medications have been purchased within a time window of, e.g. one week (84, 
153, 248) or one year (151, 204).  
There are some widely used combinations of psychotropic medications. 
For example, the combination of antidepressants and benzodiazepines can be 
used in the acute phase of depression (19), and in anxiety disorders (103). The 
combination of antidepressants and antipsychotics has been used in 
psychotic depression, in comorbid depression, and in borderline personality 
disorder (245), in bipolar depression (226), to reduce negative symptoms in 
schizophrenia (246), and to promote sleep in depression (242). There are several 
challenging drug-drug interactions and limited evidence-based information 
on many polypharmacy combinations (188). Especially among young people, 
there is little evidence-based information about the efficacy and safety.  
Representative surveys from the USA suggest that polypharmacy use is 
increasing both among children (57) and among adults (159). In Europe, there 
are only a few representative studies of polypharmacy use both among young 
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people (151, 204, 248, 250) and adults (92, 207). On the whole, the comparison of 
polypharmacy use across populations is very difficult, as most studies have 
been limited to specific clinical settings (75, 95, 117, 211), and the classification of 
polypharmacy has varied (229). 
A population-based register study from Iceland reported a polypharmacy 
proportion of 18% among 0- to 17-year-old psychotropic medication users in 
2007 (250). In a nationwide survey of physician visits of 6-17-year-olds in the 
USA, it was reported that polypharamacy was prescribed during 20% of the 
visits in 2004-2007 (57). In a country comparison of 0- to 19-year-old 
psychotropic medication users in 2000, the proportion who used medication 
from different medication classes was 19% in the USA, 9% in the 
Netherlands, and 6% in Germany (248). In sum, most population-based 
studies have reported the proportion of polypharmacy use among 
psychotropic medication users (57, 151, 159, 204, 248, 250). There are no previous 
reports of the cumulative incidence using a nationwide cohort from early 
adolescence to young adulthood. 
2.1.3 PSYCHIATRIC HOSPITAL TREATMENT 
Psychiatric hospital treatment (PHT), i.e. inpatient treatment of psychiatric 
disorders, indicates a severe psychiatric disorder (37). Adolescent and young 
adult patients who are treated for psychiatric disorders in hospitals are often 
diagnosed with psychotic, affective (186), and comorbid disorders, and often 
have high rates of aggressive behavior (96) or suicidalal behavior (171).  
In Finland, approximately 30,000 patients per year were treated for 
psychiatric disorders in hospitals between 1990 and 2003 (184). This 
corresponds to a one-year prevalence of 0.6%. The one-year prevalence of 
PHT is higher among adolescents than children, according to data from both 
Finland (232) and the USA (186). Among adolescents aged 13 to 17 years in 
Finland, the use of PHT has increased: the one-year prevalence of treatment 
in child and adolescent psychiatric inpatient units was 0.29% in 1995-1998, 
and 0.55% in 2002-2004 (232). This was mainly a result of the political 
decision in Finland to direct more public funding to adolescence psychiatry 
beginning from the early 2000s (232). In the USA, the opposite pattern in 
seen, as there has been a change towards less inpatient treatment among 
children and adolescents (152).  
2.1.4 DIRECT COSTS ASSOCIATED WITH PSYCHIATRIC TREATMENT 
The total health care costs in Finland in 2002 were summarized in a report of 
the National Institute of Health and Welfare (107). Based on information from 
the report, the health care costs of psychiatric care and other domains are 
summarized in Table 1 separately for the age groups 7-17 years and 18-40 
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years. In total, among people aged seven to 40 years, the costs of public 
psychiatric inpatient and outpatient care were 339 million € in 2002.  
 
As shown in Table 1, the costs of prescription medication were 228 million € 
in 2002 for people aged seven to 40 years old. However, the report did not 
separate the costs of psychotropic medication versus other medication (107). 
In other reimbursement statistics based on all age groups in 2009, the total 
costs of antipsychotics, benzodiazepines, antidepressants, and stimulants in 
outpatient care were 165 million €, which corresponds to 9% of the total 
prescription medication costs (1.77 billion € (122)). Generalizations to 
Review of the literature 
 22 
adolescents and young adults is however difficult to do on the basis of these 
numbers, because the statistics include all age groups and the old age groups 
represent higher total costs than the young age groups (122). The total costs of 
antidepressants and antipsychotics in all age groups were 50 million € and 
89 million €, respectively, in 2009 (122). 
According to a report from the USA, costs from psychotropic medication 
represent an increasing share of the total health costs of psychiatric disorders 
among young people (152). The proportion of psychotropic medication costs of 
the total outpatient costs of psychiatric disorders ranged between 31% and 
52% across disorders, according to a study of privately insured children and 
adolescents aged 17 or younger in the USA in 2000 (152). Therefore, the 
psychotropic medication use is of increasing public health and financial 
importance (152). 
Though only half a percent of the population are treated in psychiatric 
inpatient units per year, the proportion of psychiatric inpatient treatment 
was 10% of the total health costs. One explanation for these high inpatient 
costs is that the treatment times are often long in psychiatric inpatient care. 
For example, the mean stay per year in psychiatric inpatient units was over 
60 days per treated adolescent (232). Given that the mean cost per day of 
psychiatric hospital treatment was 451 € in adolescent inpatient units and 
266 € in adult inpatient units in 2006 (106), the cost of one inpatient 
treatment period for one patient is often tens of thousands of euros.  
2.2 CHILDHOOD PREDICTORS OF PSYCHIATRIC 
PROBLEMS BY YOUNG ADULTHOOD 
First, a methodological overview of how childhood predictors of adult 
psychiatric problems have been studied is presented. Second, population-
based studies on mental health problems in childhood and psychiatric 
problems are presented. Third, because there is a scarcity of information 
about the predictors of psychotropic medication use and PHT, a review 
including a wider outcome, psychiatric problems in adulthood, is presented. 
The reviewed outcome, adult psychiatric problems, has mainly been 
measured using diagnostic interviews or register-based information on a 
specific disorder, such as schizophrenia. A variety of childhood predictors of 
adult psychiatric problems are presented: prenatal events, neurological 
development, cognitive abilities, school performance, family-related factors, 
childhood mental health problems, and bullying and victimization. 
Throughout these sections, sex-specific differences are brought up. Fourth, 
the main theme of this thesis, associations between childhood mental health 
problems and psychotropic medication use and PHT in adulthood, is 
presented. 
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2.2.1 CONCEPTS AND METHODOLOGY 
In the study of associations between childhood and adult mental health 
problems, variables of characteristics in childhood and variables of 
characteristics in adulthood are analyzed. Thereby, the terms predictor and 
predictive association are often used. These childhood predictors of adult 
problems can be conceptualized in different ways (223). One possibility is that 
they are antecedents of adult problems (223), e.g. are childhood depressive 
symptoms early manifestations of depressive disorders in adulthood? A 
second possibility is that they are mediating factors between previous factors 
and adult problems (223), e.g. is genetic susceptibility to depression in 
adulthood mediated by childhood depressive symptoms? A third possibility 
is that they are independent risk factors (223), e.g. do depressive symptoms 
independently predict adult depressive disorders when other possible risk 
factors are taken into account? Whether the predictive factors are 
conceptualized as antecedents, mediators, or independent risk factors 
depends on the study question (223). Because it is not completely clear which 
developmental risk factors interact and predict mental disorders in 
adulthood (66), this review will not distinguish between antecedents, 
mediators, and independent risk factors. The review will focus on main 
effects between childhood risk factors and adulthood mental health 
problems. 
2.2.1.1 Study designs 
The continuity of childhood problems to adult adverse outcomes can be 
studied using different designs (223). The focus in this literature review is on 
prospective, i.e. longitudinal, studies, which start by gathering information 
about predictors and then follow up the sample.  
The two most often used prospective study designs to study childhood 
predictors of psychiatric outcomes in adulthood have been clinical cohort 
studies and population-based cohort studies. In a clinical cohort study, 
patients who present with a specific feature (e.g. childhood depression) are 
chosen from a clinical setting (e.g. a hospital clinic). Controls without the 
specific feature (e.g. without childhood depression) are usually matched with 
the patients, meaning that the controls should be as similar as possible to the 
patients with regard to, e.g. age and sex. Finally, the cohort of patients and 
controls is followed up and information about the outcome is gathered. 
Because the patients are chosen from a clinical setting, the major 
disadvantage of the clinical cohort design is that the results are usually not 
generalizable to the general population, as only a small proportion of 
children with, e.g. depression are treated. 
In population-based studies, a fraction of the total population is studied 
regardless of help-seeking or treatment. Because only a minority of children 
with mental health problems is treated (220), such designs are especially 
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valuable in longitudinal child psychiatric studies because the results are 
representative of the total population and not only of those who receive 
treatment. Furthermore, if the aim is to analyze a full picture of risk factors 
and protective factors, population-based studies are needed. Some 
population-based studies have been named birth-cohort studies. There are 
several definitions of birth-cohort studies, but the essential factor is that a set 
of births is followed up (56). Although the first assessment is ideally done 
already during pregnancy, the timing of the first assessment can vary 
depending on the study questions (56).  
2.2.1.2 Informants of childhood mental health problems  
Agreement between parents and children in reporting psychiatric problems 
is usually low (3). Generally, it is considered that children’s self-reports of 
psychopathology, especially depressive symptoms, become more important 
the older the children get (212, 235). On the other hand, a child with disruptive 
problems might himself or herself not consider them as problems at all. 
However, there is no “optimal informant” (36). Different informants simply 
perceive the behavior of the child differently (138). Most disorders, regardless 
of whether they are obtained from interviews with parents or children, are 
usually clinically valid and associated with impairment (114).  
2.2.2 POPULATION-BASED STUDIES FROM CHILDHOOD TO 
ADULTHOOD 
Prospective population-based studies from childhood to adulthood are 
summarized in Table 2. First, an overview of the Finnish population-based 
longitudinal studies from childhood to adulthood is shown. Finnish studies 
without questionnaire- or interview-based data of childhood 
psychopathology are also presented, to show the possibilities of longitudinal 
research in Finland. Second, international population-based cohorts with 
more than 1,000 subjects and psychopathology measures in both childhood 
and adulthood are described. 
In Finland, there are a number of longitudinal population-based studies. 
The oldest cohorts are from Helsinki. Children born between 1924 and 1933 
(236) and between 1934 and 1944 (32, 83, 191, 192) in Helsinki University Central 
Hospital have been followed up to adulthood. These two birth cohorts have 
focused to a great extent on prenatal and childhood growth patterns and the 
development of mental (192, 236) and cardiovascular disorders (32, 83). They have 
utilized manually collected case notes to obtain pregnancy and childhood 
variables, and register- (236) and questionnaire-based data (192) to obtain 
information about psychiatric outcomes in adulthood. A third cohort 
includes children born in Helsinki between 1951 and 1960; it has been 
followed up with regard to school performance and later mental disorders 
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according to register-based data (47). A fourth birth cohort from Helsinki 
consists of children born in 1955 and followed up to age 21 using, e.g. 
register-based information about hospital admissions, social services and 
criminal offences, and questionnaire-based information about psychiatric 
symptoms at age 21 (6, 7, 18). The Jyväskylä Longitudinal Study of Personality 
and Social Development was started in the 1960’s and has followed up the 
sample of approximately 350 subjects to age 42 with almost no attrition (185, 
190). In Northern Finland, the population-based Northern Finland Birth 
Cohorts 1966 (NFBC 1966) (110, 150) and 1986 (NFBC 1986) (105, 108, 136, 149), 
consisting of some 10,000 subjects, have been followed up since birth. The 
NFBC 1966 has comprehensively utilized case records from childhood and 
register linkages (110, 150). In the NF 1986, questionnaire-based data on 
psychopathology at the ages of eight and 16 have also been gathered (149). In 
addition to the population-based cohorts described in Table 2, a longitudinal 
study of 1,261 adolescents aged 16 has been followed up in Tampere (109, 180). 
Also new Finnish cohort studies are being conducted (80, 87, 142). In summary, 
many Finnish cohort studies have been large and representative, utilizing the 
personal identification number to link information from several registers and 
manually collected case notes. Finally, the participation rates in 
questionnaire-based studies have been rather high. 
The methodology of the international studies varies considerably with 
regard to settings, sampling design, number of subjects, follow-up rates, 
timing and numbers of assessments, as well as measurements of 
psychopathology and other variables of interest. Few studies have included 
over 1,500 subjects. An exception to this is the 1958 British Birth Cohort, 
which originally included over 17,000 subjects (55, 78, 115). The follow-up rates 
have mainly varied depending on the methods used. For example, studies 
with diagnostic interviews have followed up between 66% and 95% of the 
original study samples (11, 61, 85, 86, 157), while studies utilizing medical records 
have managed to track virtually all with correctly documented personal 
information (78). A major strength of some of the studies is the assessment of 
psychopathology multiple times throughout the development. For example, 
abnormal behavior was first assessed at the age of three in the Dunedin 
study, and different measures related to mental health have later been 
assessed at the ages of 5, 7, 9, 11, 13, 15, 18, 21, 26, and 32 (51, 132, 155, 157, 167). 
Also in the Zuid-Holland study, psychopathology has been assessed five 
times between 1985 and 2007 for several age cohorts, i.e. the members were 
three years old in the youngest age cohort and 17 years old in the oldest 
cohort at baseline in 1985 (11, 76, 194, 198, 235). A further strength in some studies 
is the use of diagnostic interviews, which yield more reliable data on 
psychopathology than do questionnaires. For example, diagnostic interviews 
were conducted at eleven time points between 1993 and 2005 in the Great 
Smoky Mountain study (61, 67). In sum, the studies with most detailed 
information have had smaller sample sizes than, e.g. the 1958 British Birth 
Cohort (55, 78, 115). Of note, in addition to the cohorts cited above, members of 
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several cohorts are reaching adulthood currently or in the near future. 
Examples of some population-based cohorts are the ALSPAC- (26), the 
TRAILS- (231) and the Generation-R-cohorts (94).  
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2.2.3 FAMILY-RELATED GENETIC AND ENVIRONMENTAL FACTORS 
AS PREDICTORS
Psychiatric disorders tend to run in families (237). Families share both genetic 
and environmental factors, which in some cases are stressful life events. 
According to current knowledge, stressful life events and genetic factors 
combine or interact and thereby increase the risk of psychiatric disorders (51, 
125).  
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In addition to the gene-environment interplay (29), the environmental 
factors tend to cluster. That is, single environmental risk factors, such as 
family violence and weak parent support (244), often correlate with each other. 
Different environmental factors act through several pathways. For example, 
living with a single parent during childhood increases the risk of psychiatric 
disorders in adulthood (239), but the increased risk can to a large degree be 
explained by other factors, which are associated with both single parenthood 
and psychiatric problems among offspring. Such family characteristics or 
stressful life events include socioeconomic disadvantage (187), financial 
problems (63), death of parent (123, 124), weak parent support, parent-child 
discord (244), and childhood abuse (85). Furthermore, it is of note that not all 
family factors are risk factors; some are protective factors. For example, 
stimulating activities can reduce the risk of mental health problems (133). 
2.2.4 PRE- AND PERINATAL FACTORS AS PREDICTORS 
Especially in the research on schizophrenia, a number of risk factors have 
been found that occur before birth (29, 41). These include, e.g. advanced 
paternal age (40), maternal infections during pregnancy (42), low birth weight 
(1, 236), and obstetric complications (48). However, some recent studies indicate 
that, e.g. smoking during pregnancy (80) and low birth weight (1) predict not 
only psychotic disorders, but also a wide range of non-psychotic disorders in 
adulthood.  
2.2.5 EARLY DEVELOPMENT AND COGNITIVE ABILITIES AS 
PREDICTORS 
Delays in developmental milestones, e.g. learning to walk late, are associated 
with schizophrenia in adulthood (116). These results have been replicated: 
delayed early motor development seems to predict specifically schizophrenia, 
while it is not strongly associated with adult mania, depression, or anxiety 
(46). Also poor performance in sports and handicrafts in elementary school 
(47), low educational test scores between age 8 and 15 (116), and low 
intelligence quotient (IQ) between age 3 and 11 (46) have shown associations 
with adult schizophrenia.  
2.2.6 CHILDHOOD MENTAL HEALTH PROBLEMS AS PREDICTORS  
The term problem is used below to describe both symptoms and disorders 
related to mental health. 
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2.2.6.1 Externalizing problems 
Externalizing problems refer to acting-out behavior. Externalizing disorders 
include conduct disorders and oppositional defiant disorders. In addition, 
attention deficits and hyperactivity are also externalizing problems, but are 
often categorized as a separate entity from other externalizing problems. 
Conduct disorder constitutes a wide spectrum of “repetitive and persistent 
patterns of behavior in which the basic rights of others or major age- 
appropriate societal norms or rules are violated” (14). Conduct problems in 
childhood are strongly linked to conduct problems in adolescence and 
antisocial personality disorder in adulthood, but some problems do not start 
until adolescence, while others are limited to childhood (156). There is 
evidence supporting the view of distinguishing between childhood-onset/life-
course persistent, adolescent-onset and childhood-limited conduct problems 
(156, 167, 168). According to results from the Dunedin study, the group with 
childhood-onset/life-course persistent problems has poorer mental and 
physical health in adulthood than the group with adolescent-onset conduct 
problems (167, 168). Other studies from childhood to adulthood have also 
shown that childhood conduct problems predict schizophrenia and other 
psychotic disorders, mood disorders, substance-related disorders, 
personality disorders, suicidality, and criminality (46, 100, 132, 167, 205). However, 
some studies have reported that the association between childhood conduct 
problems and adult emotional problems is different among males and 
females (2, 76, 244), while others have found no sex differences (55, 86, 132, 194). 
According to some studies, conduct problems in childhood predict emotional 
problems in adulthood among males, but not among females (2, 76, 244). 
Similarly, some studies have shown an association between childhood 
conduct problems and adult psychotic disorders among males, while the 
association has been weak among females (78, 174). 
Attention-deficit/hyperactivity disorder (ADHD) is characterized by 
inattention, such as difficulty focusing on a task and distractibility, 
hyperactivity, and impulsivity, such as restlessness and excessive talking (34). 
Attention-hyperactivity problems in childhood predict several adverse 
outcomes in adulthood (81, 146). However, both some clinical (35) and some 
population-based studies (194) have shown that attention-hyperactivity 
problems alone do not have such a strong predictive value for adult 
outcomes. That is to say, the prognosis of ADHD may be poor if ADHD 
presents together with other disorders, e.g. the frequently present 
combination of ADHD and oppositional defiant disorder (35). However, 
“pure” ADHD may have little impact on adversities in adulthood. 
2.2.6.2 Internalizing problems  
Internalizing problems include emotional problems such as depression and 
anxiety disorders. Both clinical (183, 238) and population-based (55, 132) studies 
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have shown a strong association between childhood emotional problems and 
similar adult problems. Chilhood internalizing problems have been reported 
to predict psychotic disorders in adulthood (46, 132). Some studies suggest that 
childhood emotional problems are associated with psychotic disorders in 
adulthood especially among females, while the association is less strong 
among males (78, 174). Childhood internalizing problems also predict 
suicidality (88, 217) 
2.2.6.3 Comorbid externalizing and internalizing problems  
Comorbidity refers to the co-occurrence of two or more different conditions 
(20). In psychiatric research, study groups with and without comorbidity are 
often compared (113). The subgroups with and without comorbidity have been 
studied as to whether they differ with regard to, e.g. risk factors, prognosis, 
treatment response, and neurophysiological characteristics (113). The study of 
children with combined conduct and emotional disorders provides one 
example of such a research field. Children with comorbid conduct and 
emotional problems have shown an increased risk of several adverse 
outcomes, compared to children with "pure" disorders, that is to say, 
children without comorbidity (82, 88, 90, 91, 214, 217). During recent years, this 
“mixed conduct and emotional disorder” among children and adolescents has 
also been called “dysregulation”, “irritable” and, controversially, “bipolar 
disorder not otherwise specified” (225). For the term “severe mood 
dysregulation”, diagnostic criteria for research purposes have been developed 
(145). Severe mood dysregulation is characterized by high levels in all three 
domains of mood problems (e.g. sadness), hyperarousal (e.g. agitation) and 
reactions to negative stimuli (e.g. aggression towards people or property) 
(145). Using these criteria, it has been shown that the severe mood 
dysregulation entity in childhood predicts a wide range of disorders in 
adulthood (11) and shows specific profiles in neuroimaging studies (145). 
However, to test whether severe mood deregulation can be verified as a 
distinct clinical syndrome, further observational studies and treatment trials 
are needed (145). 
2.2.7 BULLYING AND VICTIMIZATION  
Bullying has been defined as a repetitive, non-provoked, aggressive act in an 
interpersonal relationship, where there is an imbalance of power, i.e. the 
victim cannot defend him- or herself (208). Thus, the phenomenon of bullying 
is complex and includes aspects of both behavior (bullying) and stressful life 
events (victimization). Males are more involved in physical bullying, while 
bullying among females involves more relational forms of bullying such as 
social exclusion and verbal bullying (134, 164).  
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In cross-sectional studies, bullying and victimization are shown to be 
associated with poor family functioning (196), domestic violence (27), and 
parental maltreatment (206). There are very few prospective studies of 
childhood bullying behavior and victimization and their impact on later 
problem behavior and poor health. Kim and colleagues followed bullying, 
victimization, and psychiatric problems among seventh and eighth grade 
students for ten months (131). They concluded that bullying and victimization 
cause psychiatric problems rather than that psychiatric problems cause 
bullying and victimization (131). Olweus followed up 87 men from grade nine 
to age 23 and concluded that victimized boys had depression more often as 
adults than non-victimized boys (175). In previous studies of the males in the 
Finnish 1981 Nationwide Birth Cohort (the From a Boy to a Man study), 
bullying predicted outcomes that indicated an antisocial tendency in young 
adulthood (215, 216). However, these studies did not include the females in the 
sample, because the follow-up was restricted to males using mainly 
information from military call-up health examinations (215, 216).  
2.2.8 CHILDHOOD MENTAL HEALTH PROBLEMS AS PREDICTORS 
OF PSYCHOTROPIC MEDICATION USE AND PSYCHIATRIC 
HOSPITAL TREATMENT BY YOUNG ADULTHOOD 
Previous child psychiatric birth cohort studies have not reported on 
childhood mental health problems as predictors of psychotropic medication 
use in adulthood. With regard to childhood mental health problems and later 
PHT, there are some previous studies. Clinical cohort studies have shown 
that children with a psychiatric diagnosis are at risk of PHT in adulthood (135, 
238). The only large-scale prospective birth cohort study examining childhood 
predictors for later PHT with a follow-up extending to adulthood is the UK 
National Child Development Study (UKNCDS) (78). The study included all 115 
cohort members who had been treated for schizophrenia, affective psychotic 
disorders, and neurotic disorders in a hospital, and 1191 randomly selected 
controls from the original cohort of over 15,000 subjects with childhood data. 
Among males, teacher reports of externalizing and internalizing problems 
both at age seven and age eleven predicted hospital treatment of psychosis or 
neurotic disorders before the age of 28. Conversely, among females, 
internalizing problems at age seven did not substantially increase the 
likelihood of PHT. 
There is a scarcity of gender-specific data on childhood mental health 
problems as predictors of PHT, since PHT is a rather rare phenomenon in 
adolescence and young adulthood, and the number of subjects has not 
exceeded 1,500 participants in most population-based birth cohort studies 
with information about both childhood psychopathology and adult 
psychiatric outcomes. Moreover, the impact of comorbid conduct and 
emotional problems on later PHT is not known, though childhood comorbid 
conduct and emotional problems increase the risk of several adult adverse 
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outcomes (82, 88, 135, 214, 217). Lastly, in the UKNCDS, childhood mental health 
problems were assessed using only teachers as informants. However, 
information about childhood mental health problems should be based on 
standardized tools from several informants (65).  
2.2.8.1 Childhood predictors of costs associated with health service 
use 
Only a few studies have studied the impact of childhood problems on later 
acquired health care costs (135, 146, 205). Scott and his colleagues (205) used the 
population-based Inner London cohort study. Children with and without 
conduct disorder at the age of ten in 1970 were followed up to age 28. Health 
care costs were estimated by asking the subjects as adults about the 
frequency of different medical treatments. The information about the 
medical treatment was then multiplied with unit costs for general and 
psychiatric inpatient and outpatient treatment. The study showed that the 
mean health care costs among children with conduct disorder was almost 
nine times higher as adults compared to children without conduct disorder. 
Leibson and colleagues (146) identified 309 children (mean age 7) with 
ADHD in 1987 using school and medical records in Minnesota, USA. These 
were compared with children in the community who did not have ADHD. 
The cases and the controls in the cohort were followed up to the year 1995 
(mean age 15). Medical care costs were derived from databases including 
inpatient, outpatient, and emergency department care. Information on 
health costs was almost complete, except for information from a few private 
practitioners, which could not be included in the study. The study showed 
that the median medical care costs incurred by children with ADHD were 
approximately twofold compared to children without ADHD. 
Knapp and colleagues (135) studied long-term costs among children and 
adolescents (mean age 14) treated in the Maudsley clinic in London between 
1970 and 1983. The costs of medical care were assessed by asking the 
subjects as adults about different medical treatments after the age of 17 and 
then transcribing them to costs in a similar way to that done in the study by 
Scott et al. (205). Cost comparisons were made between children who had 
depression versus comorbid conduct disorder and depression. The study 
showed that the medical care costs in adulthood were approximately twice as 
high for the comorbid conduct-depression group compared to the pure 
depression group.  
None of these three studies assessed prospectively the predictors of 
psychotropic medication costs. However, costs from psychotropic medication 
use represent an increasing share of the total health costs (152). The 
proportion of psychotropic medication costs of the total outpatient costs 
ranged between 31% and 52% across psychiatric disorders, according to a 
study of privately insured children and adolescents aged 17 or younger in the 
USA in 2000 (152). 
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3 AIMS OF THE STUDY 
1. To study the cumulative incidence of different psychotropic medication 
classes and polypharmacy use of psychotropic medications by the age of 25 
(study I). 
 
2. To study how many of the antipsychotic users have been treated for 
psychiatric disorders in hospitals (study II). 
 
3. To study family characteristics and psychopathology measures at the age 
of eight as predictors of antipsychotic use, antidepressant use, and hospital 
treatment of psychiatric disorders by the age of 25 (studies II-IV). 
 
4. To study whether antidepressant costs can be predicted by family 
characteristics and psychopathology measures at the age of eight, when 
predictors of antidepressant use are taken into account (study III). 
 
5. To study whether bullying behavior and victimization at the age of eight 
predict psychotropic medication use and hospital treatment of psychiatric 
disorders by the age of 25 (study V).  
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4 METHODS 
4.1 STUDY DESIGN 
The thesis is part of the multicentre 
“Finnish Nationwide 1981 Birth Cohort 
Study” (8, 221). A history of the cohort is 
presented in Box 1. As shown in Figure 
1, the population of the study was all 
60,007 Finnish children born during 
1981 and alive in 1989 (8). A 
representative sample of 6,017 children 
was invited to take part in the study in 
1989, i.e. 10% of the population. This 
representative sample of 8-9-year-old 
children came from all five university 
hospital areas in Finland (Helsinki, 
Turku, Tampere, Kuopio, and Oulu). To 
assure representativeness of the general 
population, the communities in the 
hospital areas were selected according 
to their degree of urbanization. In small 
communities, all children born in 1981 
were selected, while in larger cities, a 
random sample of school classes was 
selected from all school districts of the 
city. The sociodemographic 
characteristics of the sample are 
representative of the population (8).  
Of the 6,017 subjects in the original 
sample, the study sample in 1989 
consisted of 5,813 subjects with 
questionnaire-based information; these 
subjects represented 97% of the original 
sample. As shown in Figure 1, 
altogether 70 subjects were never 
reached due to migration or unknown 
address (1.2%) and 134 refused to 
participate in the study (2.2%) (8).  
The study sample between 1994-
2005 included 5,525 subjects whose 
Box 1 History of the Finnish 
Nationwide 1981 Birth Cohort Study 
 
The sample used in this thesis derives 
from the Finnish Nationwide 1981 Birth 
Cohort Study (FN1981BCS). To put this 
study in context, a brief history of the 
cohort may be valuable. The purpose of 
the original study in 1989 was to 
investigate the prevalence of psychiatric 
problems among eight-year-old 
children. Later the sample has been 
part of time-trend studies, local follow-
up studies, and nationwide follow-up 
studies.  
Time-trend studies of eight-year-old 
children’s psychiatric and 
psychosomatic symptoms in 1989, 
1999 and 2005 have been conducted in 
Turku using questionnaires 
(220)
. The 
local subsamples have been followed 
up with questionnaires in Turku in 1995 
(213)
, in Kuopio in 1993 and 1996 
(140)
, 
and in Helsinki in 1994 
(177, 209)
. The 
nationwide follow-up studies consist of 
two parts: the From a Boy to a Man 
study including the males in the sample, 
and the current register-based sample 
including both males and females and 
named the FN1981BCS. The From a 
Boy to a Man Study was first conducted 
at military call-up in 1999 when the 
male participants completed 
questionnaires about their mental 
health 
(219)
. Later, the male sample was 
further studied regarding, e.g. 
psychiatric diagnoses according to 
military registers and crimes according 
to the police register 
(214)
.  
In the current FN1981BCS, the 
available personal identification 
numbers were linked to several 
nationwide registers, including, e.g. the 
hospital discharge register, the causes 
of death register, and the drug 
prescription register. Studied outcomes 
are, e.g. suicide 
(217)
, psychiatric 
hospital treatment 
(97)
, psychotropic 
medication use 
(98)
, and teenage 
motherhood 
(144)
. 
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Figure 1 Flow-chart of the study participants. PIN, personal identification 
number. 
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personal identification numbers were linked with the National Prescription 
Register and the Finnish Hospital Discharge Register. Altogether 492 
personal identification numbers (PIN) of the original sample had been either 
lost or inappropriately documented (8.2% of 6,017). The attrition at follow-
up was due to random error, such as inappropriately documented PINs. The 
number of subjects with available data in 1989 and between 1994 and 2005 
depended on the used measurements; detailed information is given in the 
tables in the original publications (II-V). 
4.2 ETHICAL CONSIDERATIONS 
The Joint Commission on Ethics of all five university hospital units and 
clinics included in the study (Helsinki, Turku, Tampere, Kuopio, and Oulu) 
approved the research plan at baseline. At follow-up, Turku University and 
Turku University Central Hospital approved the research plan. The combined 
information from questionnaires and registry data was analyzed in such a 
way that no subject could be identified. 
4.3 MEASURES IN 1989 AT AGE EIGHT 
Data collection in 1989 was organized through teachers, when the subjects 
attended the second grade in elementary school. The teacher sent parent 
questionnaires via the child to the parents, and the parents returned the 
questionnaire with the informed consent in a sealed envelope to the teacher. 
The children filled in a questionnaire in the classroom. The teacher sent the 
parent questionnaires in sealed envelopes, the teacher questionnaires, and 
the child self-reports to the researcher. Parents and teachers filled in brief 
questionnaires on a variety of mental health problems and additional 
questions on bullying and victimization. The children filled in a 
questionnaire on depressive symptoms and additional questions on bullying 
and victimization.  
4.3.1 PSYCHIATRIC SYMPTOMS 
Psychiatric symptoms at age eight were assessed using information collected 
from three different sources: parents, teachers, and children. The parents 
and the teachers completed the Rutter’s parent questionnaire (RA2) (202) and 
the teacher-questionnaire (RB2) (200), respectively. Both scales are validated 
in Finland (139) and have been widely used in child psychiatric research (89). 
The parent questionnaire consists of 31 and the teacher questionnaire of 26 
items on a scale ranging from 0 to 2 points. The correlation between the total 
score on the parent and teacher scales was r=0.36 among males and r=0.26 
among females (141). In addition to the total score scale, there are three 
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subscales. The conduct scale has questions about stealing, lying, aggression, 
defiance; the hyperactivity scale is concerned with restlessness, 
distractibility, inattention; and the emotional scale addresses shyness, 
withdrawal and anxiety.  
The children themselves filled in the Children’s Depression Inventory 
(CDI), which measures depressive symptoms (137). The original English 
version of CDI has shown good validity for assessing depressive symptoms 
among children (62). According to a Finnish study, the CDI can be used as a 
measure of overall psychiatric disturbance, but only if it is combined with 
information from other informants (139).  It has 27 items on a scale ranging 
from 0 to 2 points. The core research committee excluded the question 
concerning suicidal ideation from the version used in this study. It was 
considered to be ethically unreasonable to ask children a question about 
suicidal ideation at that age in a classroom setting, especially without an 
opportunity to discuss the issue with an adult. In sum, the version used in 
this study had a maximum score of 52 points.  
4.3.1.1 Variable-centered approaches 
In studies II-IV, variable-centered approaches were used. Variable-centered 
approaches are suitable, e.g. to describe the relative importance of predictor 
variables in explaining the variance of an outcome variable (143). 
Total scores of the parent and teacher scales: To study general 
psychopathology or possible caseness, the total scores of the parent and 
teacher scales were used. In study IV, the children were divided into screen-
positive and screen-negative groups based on the total scores of the parent 
and teacher reports (males (M): n=2638; females (F): n=2554). A cut-off 
point of 13 and 9 was used on the parent and teacher reports, respectively. 
These cut-off points correspond to the 85th percentile; they are commonly 
used, and validated to detect mental disorders in Finland (139). Parent and 
teacher reports were combined using an “or rule” (114, 243), i.e. subjects were 
classified as screen- positive if the points in either the 1) parent report, 2) the 
teacher report, or 3) both reports were above the cut-off score (M: 29.6%; F: 
12.6%). The proportions of screen-positive and screen-negative subjects have 
been described in detail in a prior report (9). 
In study V, the total scores on the parent and teacher scales were used as 
possible confounding variables. When used as linear variables, the parent 
and teacher total scores were summed together. When used as categorical 
variables, the subjects were classified as screen-positive or -negative in the 
same manner as described above (study IV). 
Summed subscales and the CDI: To study specific types of 
psychopathology, the three subscales of the parent and teacher reports and 
the CDI were used. In studies II and IV, the scores from the parent and 
teacher conduct, hyperactivity and emotional subscales were summed 
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together to generate the three pooled scales (parent conduct scores + teacher 
conduct scores = pooled conduct score etc.), while the depressive scale was 
based on the child self-report alone. These scales were studied as both linear 
variables to achieve statistical power and as categorical variables to facilitate 
the interpretation of the results for screening purposes. In line with previous 
reports using categorical variables (214, 217), sex-specific cut-off scores at the 
90th percentile based on the distribution in the population-based sample at 
baseline were used. 
Standardized scales: In study III, the four scales were standardized, 
because the range of potential scores on the conduct, hyperactivity and 
emotional scales were different for parents and teachers. Through 
standardization, the conduct, hyperactivity, and emotional scales were given 
equal weight from each informant. All standardization procedures were done 
separately for males and females. The three subscales of the parent and 
teacher scales and the CDI were standardized by subtracting the mean value 
of the scale from the observed value of the subject, and finally by dividing 
with the standard deviation of the scale (e.g. standardized parent report of 
conduct symptoms = (observed value - mean value) / standard deviation). 
The final standardized pooled scales (conduct, hyperactivity and emotional) 
were generated by taking the average score of the standardized parent 
subscale and the corresponding teacher subscale (e.g. pooled standardized 
conduct scale = (standardized parent report of conduct symptoms + 
standardized teacher report of conduct symptoms) / 2). If information from 
only the parent or the teacher but not both was available, the pooled scale 
was not generated for the subject concerned. The standardized pooled scales 
were studied both as linear variables and as categorical variables. When 
using categorical variables, sex-specific cut-off scores at the 90th percentile 
were used.  
4.3.1.2 Person-centered approach 
In study IV, person-centered approaches were used. Person-centered 
approaches take into account that the heterogeneity of the population might 
affect the prediction of an outcome (143). The predictor “conduct problems” 
can serve as an example: a group of persons with “pure” conduct problems 
may be heterogeneous compared to a group with both conduct and emotional 
problems with regard to an outcome (214). Likewise, mental health symptoms 
reported by adults or reported by the children themselves may predict an 
outcome differently (214). The four summed psychopathology scales using the 
sex-specific 90th percentile cut-off points were combined to form 16 
combinations (M: n=2544; F: n=2478). As shown in Figure 2, these 16 
groups were a priori collapsed into six clinically meaningful groups in line 
with previous reports (214, 217):  
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1. The Reference group was negative (below the 90th percentile) on all 
four scales; 
2. The Conduct-Emotional group was conduct-positive and emotional-
positive or CDI-positive, indicating a high level of symptoms in both 
conduct and emotional domains; 
3. The Conduct-only group was positive on the conduct scale, but 
negative on both the emotional scale and the CDI 
4. The Attention-Hyperactivity group was positive on the hyperactive 
scale, but negative on the conduct scale 
5. The Emotional-only group was positive on the emotional scale and/or 
the CDI, but negative on conduct and hyperactivity scales 
6. The Invisible group had high levels of self-reported depressive 
symptoms, but was screen-negative on all three scales based on adult 
reports. 
 
 
 
Figure 2 The criteria of belonging to different groups of childhood 
psychopathology in the person-centered approach. CDI, Children’s Depression 
Inventory. 
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4.3.2 BULLYING AND VICTIMIZATION  
In study V, information from all three informants, i.e. the parent, the teacher 
and the children themselves, was used to assess bullying and victimization. 
In the Finnish versions of the parent and teacher reports, a question about 
bullying and another about victimization were included: “The child bullies/is 
bullied”. The answer alternatives were (1) “doesn't apply”, (2) “applies 
somewhat”, and (3) “certainly applies”. In the self-report, bullying was 
assessed by giving the child three alternatives from which to choose: (1) "I 
bully other children almost every day", (2) "I bully sometimes", and (3) 
"Usually I do not bully". Victimization was assessed by the alternatives: 
"Other children (1) bully me almost every day", (2) "bully me sometimes", 
and (3) "usually do not bully me". Alternatives 1 and 2 were regarded as 
indicating no or only sometimes bully or victim status, whereas alternative 3 
indicated frequent bully or victim status.  
The sample was classified into the following groups: (1) those who never 
or only sometimes bully and are not victimized according to parental, 
teacher, and self-reports; (2) those who frequently bully (but are not 
victimized) according to at least one informant; (3) those who are frequently 
only victimized according to at least one informant; and (4) those who 
frequently both bully and are victimized using pooled information from all 
three informants. For example, if a boy frequently bullied according to 
teachers and was frequently victimized according to self-reports, he was 
classified into the bully-victim group. Only subjects with complete 
information about bullying and victimization from all three informants were 
included in the analysis. Combining the parent, teacher, and child reports of 
information about bullying/victimization by using the "either-or" rule is 
justified by the finding that the interrater agreement was low (weighted κ in 
range 0.11–0.22).  
4.3.3 FAMILY CHARACTERISTICS 
Information about family characteristics at the age of eight was used in 
studies II-IV and was derived from the parent report. Parental education 
level was based on information about whether the father or the mother had 
completed of at least 12 years of education or if both parents had a lower 
education level (in Finland compulsory education consists of 9-year 
comprehensive school after which education can be continued in vocational 
school or in upper secondary school concentrating on theoretical subjects). 
Family structure was based on information about whether the child lived in a 
family with two biological parents or if the family had some other 
constellation. 
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4.4 MEASURES BETWEEN 1994 AND 2005 AT AGE 12-
25 
In Finland, every citizen has a unique personal identification number (PIN), 
consisting of the date of birth and a four-digit suffix. The PIN is given at birth 
and stays the same throughout life, regardless of changes of name or place of 
residence. The PIN codes of the participants were linked to data from the 
Drug Prescription Register, the Special Reimbursement Register, and the 
Finnish Hospital Discharge Register between January 1st, 1994, and 
December 31st, 2005, when the subjects were from 12-13 to 24-25 years old.  
4.4.1 PSYCHOTROPIC MEDICATION USE 
In studies I, II, III and V, psychotropic medication use was studied. For 
convenience, the outcome, having at least one purchase of a psychotropic 
medication, is referred to as psychotropic medication use. Information about 
the use of psychotropic medication was collected from the nationwide Drug 
Prescription Register, which is filed by the Social Insurance Institution of 
Finland (SII). The register contains information about the personal 
identification number, the purchased medication, the cost of the purchase, 
and the date of the purchase. The nationwide Drug Prescription Register 
tracks medication that has been purchased from a pharmacy, and comprises 
data on 97%-98% of all reimbursed prescriptions (166). The SII reimburses 
prescription medicines that have been approved for reimbursement as 
treatment of an illness. The SII also keeps the Special Reimbursement 
Register, which includes the PINs of subjects who are granted a high level 
special reimbursement for the continuous medication of some chronic 
disorders (e.g. epilepsy and psychotic disorders). 
The medication is coded according to the Anatomic Therapeutic Chemical 
(ATC) classification system in the register (166). In study I, the use of 
psychotropic medication was classified into groups accordingly: 
1. antipsychotics (ATC-codes N05A, except N05AB01 “dixyrazine” and 
N05AN01 “lithium”);  
2. antidepressants (N06A and N06CA “antidepressants in combination 
with psycholeptics”);  
3. benzodiazepine derivates including anxiolytics (N05BA) and 
hypnotics (N05CB and N05CF);  
4. mood stabilizers (N03, except N03AE01 clonazepam; and N05CB02 
barbiturates in combination with other drugs) included antiepileptics 
that were not purchased by subjects who had epilepsy according to the 
Special Reimbursement Register; and,  
5. “other psychotropic medications” included medications, which could 
not be categorized in the above-mentioned groups or have indications 
for both psychiatric and other types of disorders (N05AB01 
“dixyrazine” which is indicated for both psychosis and nausea, 
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N05AN01 “lithium”, N05BB01 hydroxizine which is indicated for both 
anxiety and allergy, N05BE01 buspirone, N06BA04 methylphenidate, 
N07BB01 disulfiram).  
In study V, a very similar classification and terminology was used as in study 
I, but with the following differences:  
• Anxiolytics in study V refers to the same class as benzodiazepines in 
study I (the benzodiazepine class in study I included both anxiolytics, 
such as diazepam and lorazepam, and hypnotics, such as zopiclone).  
• Antiepileptics in study V refers to the same class as mood stabilizers in 
study I, but subjects who had epilepsy according to the Special 
Reimbursement Register were not excluded in study V. In study I, 
subjects with epilepsy were excluded from the mood stabilizer group. 
In the thesis as a whole, special focus was laid on the use of antidepressants, 
and antipsychotics, because they are medication classes with clear 
psychiatric indications and had the highest number of users.  
4.4.1.1 Polypharmacy use 
In study I, polypharmacy use was assessed. There is no standard width of the 
time window within which two purchases can occur to be defined as 
polypharmacy in register-based research (153, 247). In study I, a time window of 
one day was primarily chosen, in order to make comparisons with several 
surveys, which have defined polypharmacy as a physician visit with more 
than one psychotropic medication prescription (57, 92, 159). The focus was on 
across-class polypharmacy, i.e. the concomitant use of two medications from 
different psychotropic medication groups.  
4.4.1.2 Costs of antidepressant medication 
In study III, costs of antidepressant medication were assessed. The costs of 
all purchases were recorded in the Drug Prescription Register in Finnish 
Marks (FIM) between 1994 and 2001, and in euros between 2002 and 2005. 
All prices were adjusted to correspond to 2005 prices in euros, using the 
official FIM/euro exchange rate for the years between 1994 and 2001 (30), and 
adjusted for inflation using the Price Consumer Index (222). 
4.4.2 PSYCHIATRIC HOSPITAL TREATMENT 
In studies II, IV and V, psychiatric hospital treatment was studied. 
Information about psychiatric hospital treatment between 1994 and 2005 
was based on the Finnish Hospital Discharge Register in Finland, which is 
extensively documented in psychiatric research (126, 181, 217, 228). The register 
covers, e.g. the diagnosis and the day of admission in all general, mental and 
private hospital inpatient care units in Finland.  
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The outcome of “psychiatric hospital treatment” was defined as having a 
primary diagnosis of a psychiatric disorder in the hospital discharge register 
between 1994 and 2005. All patients treated according to the register were 
included in the study, i.e. both psychiatric and general hospitals were 
included. The diagnostic codes were registered according to ICD-9 in the 
years 1994-1995, and ICD-10 in 1996-2005.  
In study II, the hospital discharge register was searched for all psychiatric 
main diagnoses of subjects who had used antipsychotics during the follow-
up. The subjects were classified into the following groups:  
1. Non-affective psychoses (ICD-10 codes F20-F29; ICD-9 codes 295 and 
297-298) 
2. Affective disorders (F30-F39; 296) 
3. Other psychiatric disorders (F00-F99, except F20-F39; 290-319 
except 295-298) 
4. No inpatient treatment of psychiatric disorders (no F00-F29 or 290-
319 main diagnosis in the register during the follow-up).  
In study II, the same subject could belong to only one group, so that group 1 
overruled group 2 etc. (e.g. a subject who had been discharged with both a 
non-affective psychosis and an affective disorder during the follow-up, 
belonged to the non-affective psychotic disorder group). 
In study IV, diagnostic codes of specific diagnoses and diagnostic groups 
were classified according to the transcription of ICD-9 and ICD-10 codes to 
DSM-IV-TR diagnoses (13). The association with childhood variables was 
analyzed for having any psychiatric diagnosis and, additionally, separately 
analyzed for the four diagnostic groups with most subjects: psychosis, mood 
disorders (non-psychotic), anxiety disorders, and substance-related 
disorders.  
In study IV, subjects could belong to several diagnostic groups (some 
subjects were diagnosed with different diagnoses at different treatment 
periods). Subjects who had not been treated for a psychiatric disorder 
according to the register data between 1994 and 2005 were used as a 
reference group in all statistical analyses in study IV. 
4.4.3 POOLED OUTCOME OF PSYCHOTROPIC MEDICATION USE 
AND/OR PSYCHIATRIC HOSPITAL TREATMENT 
In study V, information about psychotropic medication use and psychiatric 
hospital treatment was pooled as a global index of psychiatric treatment at 
follow-up.  
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4.5 STATISTICAL ANALYSIS 
4.5.1 DESCRIPTIVE MEASURES 
In studies II, III, IV and V, the lifetime prevalence of the received treatment 
by the end of the follow-up was reported in percentages by dividing the 
number of users with the total number of subjects in the beginning of the 
follow-up period. In studies I and II, the cumulative incidence of medication 
use was also reported in percentages, but the cumulative incidence was 
calculated using survival analysis. 
4.5.2 SURVIVAL ANALYSIS 
The age in days of the subjects defined the survival time in all studies (I-V). 
The event was defined as the first purchase of the studied medication or the 
first psychiatric hospital treatment period. The time to moving from the 
country (n=35), death (n=35), or the end of the follow-up on December 31st, 
2005, was treated as the censored time observation. 
4.5.2.1 Cumulative incidence 
In studies I and II, the cumulative incidence and its 95% confidence intervals 
(CI) were based on survival analysis (120). The cumulative incidence was 
defined as 1 – the survival probability.  
4.5.2.2 Cox regression 
Cox proportional hazard regression models were fitted in all studies in this 
thesis (69). The associations between the predictors and the outcomes were 
quantified with hazard ratios (HR) and their 95% confidence intervals. P-
values were calculated using the Wald χ2-test. In univariate analyses, each 
predictor was analyzed separately in a model. In multivariate analyses, all 
defined predictors were entered at once into the model. 
4.5.3 COST ANALYZES 
4.5.3.1 Choice of analytical method 
In study III, the aim of the study was to predict antidepressant costs in a 
population-based sample. Thus, information on subjects who had acquired 
zero costs should also be taken into consideration. The statistical challenge 
with analyzing predictors of antidepressant costs in the total sample, is that 
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health costs, such as antidepressant costs, are extremely right-skewed (45). 
Hypothetically, the following strategies could be considered: 
1. Predicting arithmetic mean costs using a regular test, such as the t-
test, cannot be used, because the test requires a normal distribution. 
2. Predicting median costs does not require a normal distribution, but in 
this case the median equals zero.  
3. Predicting mean costs using a logarithmic transformation of the costs 
is not in line with the aim to include the total sample, i.e. also the 
subjects with zero costs (the logarithm of zero is not defined). 
4. Predicting mean costs using the bootstrap technique (31, 227) would 
enable the calculation of standard errors and confidence intervals of 
the arithmetic mean costs, even when the distribution is skewed. This 
strategy has been used in some studies (112, 135, 148, 205). However, the 
bootstrap technique does not take into account that a big proportion 
of the study population has zero costs. 
5. Predicting mean costs using sample selection models (45, 189) takes into 
account that a proportion of the study population has zero costs (45). 
Once this is taken into account, a logarithmic transformation of the 
costs can be performed (45).  
4.5.3.2 Sample selection models 
In study III, Heckman sample selection models were used to analyze 
predictors of antidepressant costs. It can be hypothesized that once the 
predictors of antidepressant use (binary variable) have been analyzed, it is 
unlikely that any further predictive value of predictors of antidepressant 
costs (linear variable) would be found.  
Sample selection models have been widely used in, e.g. econometric 
analyses (189) and to correct for drop-out in longitudinal criminological 
research (44). Among sample selection models, the most often used models 
are the two-step model and the maximum likelihood model (45). The two-step 
model is mainly used for explanatory analyses, while the more efficient 
maximum likelihood should be primarily chosen (189). In this thesis, both 
models were used for comparison of the results, as suggested (44). 
In step one of the two-step model, the inverse Mills ratio is estimated by 
predicting a binary outcome (yes/no), and in step two, the linear outcome is 
estimated, by adjusting with the inverse Mills ratio. In the maximum 
likelihood model, all parameters in the model are estimated using maximum 
likelihood estimation relying on the Newton-Raphson algorithm (230). 
To define a good sample selection model, exclusion restrictions are 
required (44). This means that some of the variables that have been used to 
predict antidepressant use (binary variable), cannot be used to predict 
antidepressant costs (linear variable). In study III, the hyperactivity and 
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emotional scales were excluded, because they had the lowest HR:s and the 
highest p-values in the Cox models. 
4.5.4 STATISTICAL SOFTWARE 
Survival analyses in studies II, III, IV and V were done with SAS System for 
Windows, release 9.1 (studies IV and V) and 9.2 (studies II and III). Survival 
analyses in study I and cost analyses in study III were done with R software, 
release 2.10.1. The cost analyses were done using the sampleSelection-
package in R (230). 
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5 RESULTS 
5.1 USE OF PSYCHOTROPIC MEDICATION (AIMS 1 AND 
2; STUDIES I AND II) 
5.1.1 CUMULATIVE INCIDENCE OF PSYCHOTROPIC MEDICATION 
USE BY AGE 25 (AIM 1; STUDY I) 
The cumulative incidences of psychotropic medication use by age 25 are 
shown in Figure 3A: the cumulative incidence of having purchased at least 
one psychotropic medication was 15.2% (n=780). The most common 
medication groups were antidepressants and benzodiazepines with 
cumulative incidences of 12.2% and 5.2%, respectively. The users of 
benzodiazepines (n=265) had used anxiolytics (n=193; cumulative incidence 
3.8%) and/or hypnotics (n=127; cumulative incidence 2.4%). More females 
than males had used any psychotropic medication (female:male HR 1.4) and 
antidepressants (female:male HR 1.6).  
Box 2 The main findings of psychotropic medication use. 
 
• 15% of this sample of Finnish people born in 1981 had used psychotropic 
medications by age 25. With regard to drug class, 2.5%, 12%, and 5% had 
used antipsychotics, antidepressants, and benzodiazepines, respectively, by 
age 25 (study I).  
• 4% had used polypharmacy combinations, i.e. two or more psychotropic 
medications concomitantly. Among psychotropic medication users, the 
proportion of polypharmacy use was 27%. The majority of antipsychotic and 
benzodiazepine users had used polypharmacy combinations, while a minority 
of antidepressant users had used polypharmacy combinations (study I).  
• Psychotropic medication use remained uncommon until late adolescence 
(study I).  
• More females than males had used antidepressants, the antidepressant-
benzodiazepine combination, and the antidepressant-mood stabilizer 
combination (study I). 
• Three-fourths of antipsychotic users had been treated for a psychiatric 
disorder in a hospital. The diagnostic groups of hospital treatment among 
antipsychotic users varied by sex: non-affective psychoses were common 
among males, while affective disorders were common among females (study 
II). 
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Figure 3 The cumulative incidence by age 25 of all psychotropic medication use 
(A) and of polypharmacy use (B, next page). Summary of Table 1 in study I. 
Abbreviations in A: Any, any psychotropic medication use; Dep., antidepressant 
use; Bnz., benzodiazepine use; Ps., antipsychotic use; Mstab., mood stabilizer use; 
Other, use of other psychotropic medications. Abbreviations in B: Any, use of any 
polypharmacy combination; Dep+Bnz, antidepressant-benzodiazepine use; 
Ps+Dep, antipsychotic-antidepressant use, Ps+Bnz, antipsychotic-benzodiazepine 
use; Dep+Mstab, antidepressant-mood stabilizer use; Ps+Mstab, antipsychotic-
mood stabilizer use. 
 
  53 
 
5.1.2 CUMULATIVE INCIDENCE OF POLYPHARMACY USE OF 
PSYCHOTROPIC MEDICATIONS BY AGE 25 (AIM 1; STUDY I) 
Polypharmacy use was defined as having purchased medications from 
different psychotropic medication classes during the same day. As shown in 
Figure 3B, the cumulative incidence of any polypharmacy use by age 25 was 
4.1% (n=210). The most common combination was the antidepressant-
benzodiazepine combination with a cumulative incidence of 2.9%. More 
females than males had used the antidepressant-benzodiazepine 
combination: the cumulative incidence was 3.5% among females and 2.3% 
among males, and the female:male HR was 1.5. The cumulative incidence of 
the antidepressant-mood stabilizer combination was higher among females 
Results 
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than among males: the cumulative incidences were 0.9% for females (n=19) 
and 0.1% for males (n=6).  
5.1.3 TIMING OF PSYCHOTROPIC AND POLYPHARMACY 
MEDICATION USE (AIM 1; STUDY I) 
The cumulative incidence of both any psychotropic medication use and any 
polypharmacy medication use started to peak in late adolescence. To describe 
this, the cumulative incidences for any psychotropic medication use by ages 
15, 20, and 25 were 1.3%, 6.1%, and 15.2%, respectively. The cumulative 
incidences of polypharmacy medication use by ages 15, 20, and 25 were 
0.2%, 1.1%, and 4.4%, respectively. As shown in Table 3, the median age in 
years of the first purchase of different medication classes ranged between 20 
and 22 years across medication classes. 
5.1.4 POLYPHARMACY USE AMONG ALL PSYCHOTROPIC 
MEDICATION USERS (AIM 1; STUDY I) 
As shown in Table 3, the proportion of any antidepressant polypharmacy 
during the same day was 33%. Among benzodiazepine and antipsychotic 
users, the proportions of any polypharmacy use were 61% and 72%, 
respectively. 
 
Table 3     The timing of the first purchase and the proportion of psychotropic medication 
users who have used polypharmacy combinations by the age of 25. 
 
Age in years at first 
purchase (median 
(IQR)) 
Proportion of users 
with polypharmacy 
usea (%) 
Users of any psychotropic medication 
(n=710) 20.6 (18.2, 22.6) 27 
Users of antidepressants (n=623) 21.2 (19.1, 22.9) 33 
Users of benzodiazepines (n=265) 21.8 (19.5, 23.2) 61 
Users of antipsychotics (n=124) 21.2 (18.7, 23.1) 72 
 
Abbreviations: IQR, inter-quartile range
  
a
 At least two medications from different medication classes purchased during the same day. 
 
5.1.5 REIMBURSEMENT DUE TO PSYCHOTIC DISORDERS AMONG 
PSYCHOTROPIC MEDICATION USERS (STUDY I) 
Psychotic disorders (e.g. documented schizophrenia, psychotic bipolar 
disorder or psychotic depression) according to the Special reimbursement 
Registers were documented among 8% of users of any psychotropic 
medication (n=62/780), 47% of antipsychotic users (n=58/124), 8% of 
antidepressant users (n=50/623), 7% of benzodiazepine users (n=19/265), 
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40% of mood stabilizer users (n=21/52), and 22% of users of psychotropic 
polypharmacy combinations (n=47/210). 
5.1.6 PSYCHIATRIC HOSPITAL TREATMENT AMONG 
ANTIPSYCHOTIC USERS (AIM 2; STUDY II) 
Among subjects with antipsychotic use, inpatient treatment of psychiatric 
disorders during the follow-up was studied. In both sexes, three-fourths of 
the antipsychotic users had been treated for psychiatric disorders in a 
hospital (76.8% among males and 74.5% among females with antipsychotic 
use). However, the diagnostic groups differed among males and females with 
antipsychotic use. Among males with antipsychotic use, 43.5% had been 
treated for non-affective psychotic disorders and 13.0% had been treated for 
affective disorders. Among females with antipsychotic use, non-affective 
psychoses were less common than affective disorders: 23.6% had been 
treated for non-affective psychotic disorders and 38.2% for affective 
disorders.  
5.2 USE OF PSYCHIATRIC HOSPITAL TREATMENT 
(STUDY IV) 
In Figure 4 it is shown that 6.2% (n=168) of the males and 4.1% (n=108) of 
the females had been discharged from psychiatric treatment. The most 
common psychiatric reason (diagnostic group) for being treated in hospitals 
among males was substance-related disorders (1.8%, n=48), while among 
females it was non-psychotic mood disorders (1.9%, n=50).  
The number of subjects who had been treated for specific psychiatric 
diagnoses, is shown in Table 4. Males (1.5%) were more often than females 
(0.8%) treated for psychotic disorders. More males than females were treated 
for non-affective psychoses (1.3% vs. 0.5%), and two of its six sub-diagnoses: 
schizophrenia (0.6% vs. 0.2%) and psychotic disorder not otherwise specified 
(0.8% vs. 0.2%). As shown in Table 5, some subjects had several inpatient 
treatment periods with different primary diagnoses.  
The mean age at the first treatment period for any psychiatric diagnosis 
was 19.1 years (SD 2.4) among males and 18.8 years (SD 3.7) among females. 
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Table 4   Number of subjects with and without hospital treatment of psychiatric disorders. 
Summary of partly unpublished results related to study IV. a, b, c 
 Males Females Sex-difference 
 % (No.) % (No.) p-valued 
Any psychiatric diagnosis 6.2 (168) 4.1 (108) <0.001 
Psychotic disorders 1.5 (40) 0.8 (22) 0.03 
Non-affective psychoses 1.3 (35) 0.5 (13) 0.002 
Schizophrenia 0.6 (15) 0.2 (4) 0.02 
Schizoaffective disorder 0.1 (2) 0.04 (1) ≈1 
Schizophreniform disorder - - NA 
Delusional disorder 0.1 (2) - 0.50 
Brief psychotic disorder 0.1 (3) 0.2 (6) 0.34 
Psychotic disorder NOS 0.8 (22) 0.2 (5) 0.002 
Affective psychoses 0.4 (10) 0.4 (11) 0.83 
Bipolar disorder with psychotic 
features 0.04 (1) 0.04 (1) ≈1 
MDD with psychotic features 0.3 (9) 0.4 (10) 0.82 
Mood disorders, non-psychotic 1.5 (40) 1.9 (50) 0.24 
Bipolar disorder, non-psychotic 0.04 (1) 0.2 (5) 0.12 
Depressive disorders, non-psychotic 1.4 (39) 1.8 (47) 0.33 
Substance-related disorders 1.8 (48) 0.9 (24) 0.006 
Alcohol-related disorders 0.7 (19) 0.3 (7) 0.03 
Cannabis-related disorders 0.3 (8) - 0.008 
Opioid-related disorders 0.3 (8) 0.3 (7) ≈1 
Other substance-related disorders 0.7 (18) 0.5 (12) 0.36 
Anxiety disorders 1.4 (37) 0.5 (14) 0.002 
Social phobia 0.1 (2) 0.04 (1) ≈1 
Panic disorder 0.2 (4) - 0.13 
Generalized anxiety 0.1 (3) 0.04 (1) 0.63 
Obsessive compulsive disorder 0.1 (2) 0.04 (1) ≈1 
Acute stress disorder 0.6 (16) 0.1 (3) 0.004 
Posttraumatic stress disorder - 0.1 (2) 0.24 
Other anxiety disorders 0.5 (14) 0.2 (6) 0.12 
Adjustment disorders 1.4 (37) 0.3 (9) <0.001 
Eating disorders - 0.5 (14) <0.001 
Personality disorders 0.4 (10) 0.2 (6) 0.46 
Cluster A 0.1 (3) 0.04 (1) 0.63 
Cluster B 0.2 (5) 0.2 (6) 0.77 
Cluster C 0.1 (2) - 0.50 
Other 0.8 (21) 0.6 (15) 0.41 
No hospital treatment 93.8 (2542) 95.9 (2528)  
Abbreviations: NOS, not otherwise specified; NA, not applicable. 
a
 Only the primary diagnosis is taken into account. The ICD-9 and ICD-10 diagnoses are classified according to 
the DSM-IV-TR transcription of ICD-codes. Please se methods for references. 
b
 Bold face indicates statistically significant differences between the sexes at p<.05. 
c
 The totals of the group percentages are > 100%, because some subjects had several treatment periods with 
different primary diagnoses. Overlapping between diagnostic groups is shown in Table 5.  
d
 Differences between the sexes of the proportions of treated subjects were analyzed with Fisher’s exact test, two-
sided p-values are given. ≈1 indicates p-values very close to 1.000 in the performed Fisher exact test. Subjects 
without the studied diagnosis were used as reference group. 
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Figure 4 The percentage of the females (n=2,637) and males (n=2,710), who 
had been treated for psychiatric disorders in a hospital during the follow-up period 
between 1994 and 2005 (aged 12-13 to 24-25 years). Summary of results in study 
IV. 
 
Table 5   Overlapping between diagnostic groups among subjects with psychiatric hospital 
treatment. 
  Psychosis Mood Anxiety Substance 
  No. %a  %a %a %a 
Males      
Psychosis 40 - 30.0 7.5 20.0 
Mood disorders, non-
psychotic 40 30.0  - 12.5 20.0 
Anxiety disorders 37 8.1 13.5 - 5.4 
Substance-related 
disorders 48 16.7 16.7 4.2 - 
Females      
Psychosis 22 - 40.9 18.2 18.2 
Mood disorders, non-
psychotic 50 18.0 - 8.0 18.0
Anxiety disorders 14 28.6 28.6 - 21.4 
Substance-related 
disorders 24 16.7 37.5 12.5 - 
 
a
 Percentage (No.) of the subjects in the rows who had also been discharged for a disorder in the columns 
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5.3 CHILDHOOD PREDICTORS OF PSYCHOTROPIC 
MEDICATION USE AND PSYCHIATRIC HOSPITAL 
TREATMENT (AIMS 3-5; STUDIES II-V) 
  
5.3.1 PREDICTORS OF ANTIPSYCHOTIC USE (AIM 3; STUDY II) 
When the sex-interactions of the childhood variables on the outcome, 
antipsychotic use, were studied, the CDI showed a statistically significant 
interaction both as a linear variable (p=0.01) and as a categorical variable 
(p=0.03). Thus, the childhood predictors were reported separately for males 
and females. 
Box 3 The main findings of childhood predictors of psychotropic medication use 
and psychiatric hospital treatment. 
 
• Both externalizing and internalizing problems, and reports by both parents and 
teachers and by the children themselves predicted a wide range of outcomes 
(studies II-V). When the linear psychopathology scales were studied in univariate 
analyses, 86% of the tested psychopathology variables among males and 61% 
among females were associated with the studied outcomes. 
• Some predictive associations were very similar in both sexes.  
o Self-reported depressive symptoms at age eight predicted hospital 
treatment of mood disorders (study IV) and antidepressant use (study 
III) in both sexes. 
o The combination of externalizing and internalizing problems at age eight 
was associated with the highest risk of later psychiatric hospital 
treatment in both sexes (study IV). 
o Living in a family with other than two biological parents predicted almost 
all studied outcomes in both sexes (studies II-IV). 
• Some predictive associations were different among males and females.  
o Externalizing problems predicted a wide range of outcomes especially 
among males (studies II-V). Also when adjusted for other psychiatric 
symptoms, conduct problems among males predicted independently 
several outcomes. Among females, conduct problems predicted 
independently hospital treatment of substance-related disorders. 
o Internalizing problems predicted many outcomes, especially among 
females (studies II-V). The self-reported depressive scale predicted 
independently hospital treatment of mood disorders and antidepressant 
use in both sexes, but among females, in addition a wider spectrum of 
outcomes, namely, PHT and antipsychotic use. 
o Being a frequent bully or a frequent bully-victim at age eight was more 
common among males than females and predicted several outcomes 
among males (study V).  
o Being a frequent victim of bullying behavior at age eight predicted a wide 
range of outcomes among females, even when the psychopathology 
scores at age eight were taken into account (study V). Among males, 
being a frequent victim modestly predicted some outcomes, but the 
associations did not remain statistically significant when 
psychopathology at age eight was adjusted for. 
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Living in a family with other than two biological parents predicted 
antipsychotic use among both males and females. Parental education level 
did not predict antipsychotic use among either males or females. The results 
for family characteristics as predictors of antipsychotic use and other 
outcomes in the thesis are summarized in Table 8. 
Figure 5 shows the results from the univariate analysis of categorical 
childhood predictors and later antipsychotic use. The same associations 
remained statistically significant when the psychopathology variables were 
analyzed as linear variables (Table 8). Among males, antipsychotic use was 
predicted by conduct, hyperactivity and emotional problems. Among 
females, the outcome was predicted by emotional and self-reported 
depressive symptoms. 
In multivariate analyses, the two family variables and the four categorical 
psychopathology scales were included in the model. Among males, family 
structure and conduct problems at age eight independently predicted use of 
antipsychotics. Among females, family structure, a high level of parent- and 
teacher-reported emotional and self-reported depressive symptoms 
independently predicted antipsychotic use. The results of the multivariate 
models of antipsychotic use and other outcomes in the thesis are summarized 
in Figure 12.  
5.3.2 PREDICTORS OF ANTIDEPRESSANT USE (AIM 3; STUDY III) 
The sex interactions between childhood psychopathology scales and 
antidepressant use were studied. Significant sex interactions were found for 
the conduct Χ sex interaction (p=0.03 for the categorical variable; p=0.004 
for the linear variable) and the hyperactivity Χ sex interaction (p=0.003; 
p=0.004). Thus, analyses were done separately for the sexes. 
Living in a family with other than two biological parents predicted 
antidepressant use among both males and females. Parental education level 
did not predict antidepressant use among either males or females. The 
results for family characteristics as predictors of antidepressant use and 
other outcomes in the thesis are summarized in Table 8. 
In Figure 6, the association between categorical psychopathology 
variables and antidepressant use is shown; family structure was included as a 
covariate in the analyses. It is shown that, among both males and females, 
the emotional and self-reported depressive scales predicted antidepressant 
use. The conduct and hyperactivity scales predicted the outcome among 
males, but not among females. Among males, the highest risk was associated 
with conduct problems, as 17.5% of the screen-positive males had used 
antidepressants, while 8.4% of the screen-negative group had done so. 
Among females, the self-reported depressive scale had the strongest 
predictive association with later antidepressant use (20.4% vs. 13.0%). The 
results for linear psychopathology variables as predictors of 
Results 
 60 
 
Figure 5 Associations between categorical psychopathology variables at age 8 
and antipsychotic use between age 12 and 25. Hazard ratios (HR) and 95% 
confidence intervals (CI) are based on univariate Cox regression analysis. The 
association is significant at p<0.05 if the 95%CI of the HR does not include 1 (the 
dotted line). Summary of Table 2 in study II. A, the conduct scale; B, the 
hyperactivity scale; C, the emotional scale; D, the self-reported depression scale, 
i.e. the Children’s Depression Inventory (CDI). 
 
antidepressant use and other outcomes in the thesis are summarized in Table 
8. 
In the final multivariate models, the family and standardized linear 
psychopathology variables that were associated with antidepressant use in 
the univariate analysis were included in the model. In both sexes, family 
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structure, the emotional scale and the self-reported depressive scale 
independently predicted antidepressant use. Among males, the conduct scale 
predicted the outcome. The results of various multivariate models of 
antidepressant use and other outcomes in the thesis are summarized in 
Figure 12. 
 
Figure 6 Associations between categorical psychopathology variables at age 8 
and antidepressant use between age 12 and 25. Hazard ratios (HR) and 95% 
confidence intervals (CI) are based on Cox regression analysis when family 
structure was used a covariate. The association is significant at p<0.05 if the 95%CI 
of the HR does not include 1 (the dotted line). Summary of figures A-C and text in 
the results section in study III. A, the conduct scale; B, the hyperactivity scale; C, 
the emotional scale; D, the self-reported depression scale, i.e. the Children’s 
Depression Inventory (CDI). 
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5.3.2.1 Predictors of antidepressant costs (Aim 4; study III) 
Table 6 shows descriptive information on lifetime antidepressant costs 
stratified by predictors at the age of eight. First, the ratio of mean costs 
between screen-positive and screen-negative subjects ranges between 1.2 (the 
hyperactivity scale) and 2.0 (the conduct scale). Females had 1.5 times higher 
lifetime antidepressant costs than males. In summary, these ratios are 
similar to the hazard ratios found in the Cox regression analysis of 
antidepressant use (binary outcome; Figure 6). Second, Table 6 shows that 
the mean costs equal costs between the 90th and 94th percentiles, indicating a 
highly right-skewed distribution of antidepressant cost. The skewness of the 
costs in the total sample (n=5,525) is further described in Figure 7A. Even 
among subjects with antidepressant purchases (n=623), the costs were right-
skewed (Figure 7B).  
To test whether the lifetime antidepressant costs (linear variable) could be 
predicted by variables at age eight, when predictors of antidepressant use 
(binary variable) are taken into account, Heckman selection models were 
fitted. The outcome was lifetime antidepressant use (binary variable) in the 
selection equation, and lifetime antidepressant costs (linear variable) in the 
outcome equation. As suggested for health care cost data (45), a logarithmic 
transformation of the lifetime costs was done (Figure 7C). In the outcome 
equations of the models, exclusion restrictions were applied, i.e. the 
hyperactivity and emotional scales were excluded from the outcome 
equations to improve the models (see section 4.5.3.2 for a more detailed 
rationale for exclusion restrictions). Both a two-step selection model and a 
maximum likelihood model were fitted to the data. The parameters of the 
models appeared well chosen, because the estimates from the two-step and 
maximum likelihood models did not vary dramatically and there were only 
seven iterations in the maximum likelihood model (under the recommended 
maximum of 15 iterations (230)).  
The main results of the maximum likelihood (ML) model are shown in 
Table 7. In the selection equation of the ML model, the conduct, emotional 
and self-reported depressive scales and sex predicted antidepressant use, and 
the standard errors (SE) were small. Table 7 shows that the SE:s in the 
outcome equation are much higher than the SE:s in the selection equation. 
The conduct scale was inversely associated with antidepressant costs, when 
the effect of having any antidepressant use was taken into account. However, 
the latter result should be interpreted with caution, because the standard 
errors were large, the level of censoring was high (4,444 censored of 5,022), 
and the two-step model did not reach statistical significance (estimate -0.41, 
SE 0.35, p=0.24). 
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Table 6   Descriptive information about the lifetime antidepressant costs in the sample. 
 Lifetime antidepressant costs (euro)a 
 Mean 
90th 
percentile 
94th 
percentile 
98th 
percentile 
Total sample (n=5,525) 60 29 200 876 
Conduct scale at age 8     
Screen negative (n=4,636) 55 14 189 806 
Screen positive (n=594) 112 139 437 1468 
Hyperactivity scale at age 8     
Screen negative (n=4,601) 60 26 209 872 
Screen positive (n=516) 71 64 221 901 
Emotional scale at age 8     
Screen negative (n=4,557) 58 23 188 843 
Screen positive (n=573) 88 163 482 1107 
Self-reported depressive scale 
at age 8     
Screen negative (n=4,636) 55 14 180 770 
Screen positive (n=594) 99 173 439 1206 
Sex     
Males (n=2,834) 48 0 98 589 
Females (n=2,691) 74 82 303 1065 
 
Note: Screen negative and positive refers to screening under and above, respectively, the cutoff score at the sex- 
specific 90
th
 percentile on the studied psychopathology scales at the age of 8. 
a
 The costs are adjusted for inflation and correspond to year 2005 euros. 
 
Table 7   Regression coefficients of the Heckman selection model, which uses maximum 
likelihood estimation (summary of the maximum likelihood selection model in Table 3 in 
study III; n=5,022). 
 
Probit selection equation 
(antidepressant use yes/no) 
Outcome equation 
(antidepressant costsa) 
Predictor Estimate SE pb Estimate SE pb 
Conduct
c
 0.25 0.07 0.001 -0.55 0.23 0.01 
Hyperactivity
c
 -0.04 0.07 0.60 
d
   
Emotional
c
 0.15 0.06 0.01 
d
   
CDI
c
 0.27 0.07 <0.001 -0.35 0.23 0.14 
Sex (male) -0.24 0.05 <0.001 0.33 0.17 0.06 
Abbreviations: CDI, Children’s Depression Inventory; SE, standard error
 
a
 The natural logarithm if the lifetime antidepressant costs on an individual level. The costs are adjusted for inflation 
and correspond to year 2005 euros. 
b 
Bold face indicates a  statistically significant association at p<0.05. 
c 
The psychopathology scales were dichotomized at the sex-specific 90
th
 percentile cutoff point. 
d 
Exclusion restrictions are applied to the hyperkinetic and emotional scales in the outcome equation.  
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Figure 7 Description of the cumulative antidepressant costs between ages 12 
and 25. The costs are adjusted for inflation and correspond to year 2005 euros. A, a 
histogram of the costs including the total sample (bar width represents 100€); B, a 
close-up histogram of the costs including the subjects with >0 costs (bar width 
represents 100€); C, a histogram of the number of subjects when the natural 
logarithm is applied to the costs. 
5.3.3 PREDICTORS OF PSYCHIATRIC HOSPITAL TREATMENT (AIM 3; 
STUDY IV) 
In both sexes, living in a family with other than two biological parents 
predicted hospital treatment of any psychiatric diagnosis. Low parental 
education level predicted hospital treatment of any psychiatric diagnosis in 
both sexes. The results for family characteristics as predictors of PHT and 
other outcomes in the thesis are summarized in Table 9. 
To study the impact of possible psychiatric caseness at age eight, the 
screening status on the parent and/or teacher report of the total score was 
studied with regard to later PHT. The sensitivity of screening positive at age 
eight on later PHT was 51.5% among males (n=84/163 with childhood data), 
while the positive predictive value (PPV) was 10.7% (HR 2.6; 95%CI 1.9-3.5; 
p<0.001). The corresponding sensitivity and PPV among females were 27.1% 
(n=29/107) and 9.0%, respectively (HR 2.7; 95%CI 1.8-4.1; p<0.001). 
Results 
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Figure 8 Cumulative incidences (A, males; B, females) and hazard ratios (HR; 
C, males; D, females) of psychiatric hospital treatment between age 12 and 25 by 
psychopathology groups at age 8. The cumulative incidences and their 95% 
confidence intervals (CI) are calculated using survival analysis. HR:s and 95% and 
their CI:s are based on univariate Cox regression analysis. The association is 
significant at p<0.05 if the 95%CI of the HR does not include 1 (the dotted line). 
Abbreviations: Cond-Emot, conduct-emotional; Cond-only, conduct-only; Attent, 
attention/hyperactivity; Emot-only, emotional-only; Invis, invisible; Ref, reference. 
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In both sexes, the categorical conduct, emotional and self-reported 
depressive scales predicted psychiatric hospital treatment of any psychiatric 
diagnosis. Among males, the categorical hyperactivity scale also predicted 
hospital treatment of any psychiatric diagnosis. When the four 
psychopathology scales were analyzed as linear variables, all scales predicted 
PHT in both sexes, as summarized in Table 8. 
In multivariate analyses, the two family variables and the four categorical 
psychopathology scales were included in the models. Among males, family 
structure, parent- and teacher-reported conduct and emotional problems 
independently predicted PHT. Among females, only the self-reported 
depressive scale independently predicted PHT. The results regarding the 
psychopathology variables in the multivariate models of PHT and other 
outcomes in the thesis are summarized in Figure 12. 
In a person-centered approach, the conduct, hyperactivity, emotional and 
self-reported depressive psychopathology scales were combined to 
disentangle the predictive value of pure versus comorbid problems and of 
parent- and teacher-reports versus self-reports. Figures 8A and 8B show the 
cumulative incidences and Figures 8C and 8D show the hazard ratios of PHT 
among the studied groups. In both sexes, the strongest predictive association 
for PHT was found for the comorbid conduct-emotional groups: the 
cumulative incidence of PHT was 21.1% among males, and 11.4% among 
females belonging to this group, while it was 3.9% and 3.2%, respectively, 
among the reference groups of males and females. Among males, also the 
conduct-only group, the attention-hyperactivity group, and the emotional 
group predicted PHT. In an additional analysis, when the effects of the 
interactions between the psychopathology types, family structure, and 
parental education level were analyzed on the main outcome PHT, no 
significant interactions were found. 
5.3.3.1 Hospital treatment of specific diagnostic groups (Aim 3; study 
IV) 
In both sexes, living in a family with other than two biological parents 
predicted hospital treatment of substance-related disorders. Among males, 
living in a family with other than two biological parents also predicted 
treatment of psychotic and mood disorders. The results for family 
characteristics as predictors of hospital treatment of a specific diagnostic 
group are summarized in Table 8. 
Figure 9 shows the hazard ratios of being treated for psychotic disorders 
(including both affective and non-affective psychoses) when the linear 
psychopathology scales at age eight were used as predictors. Among the 40 
males who had been treated for psychotic disorders, 32.5% scored above the 
sex-specific 90th percentile on the categorical conduct scale at age eight, 
28.2% on the emotional scale, and 22.5% on the hyperactivity scale. Among 
Results 
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Figure 9 Associations between linear psychopathology variables at age 8 and 
treatment of psychotic disorders between age 12 and 25. Hazard ratios (HR) and 
95% confidence intervals (CI) are based on univariate Cox regression analysis and 
represent one standard deviation change. The association is significant at p<0.05 if 
the 95%CI of the HR does not include 1 (the dotted line). A, the conduct scale; B, 
the hyperactivity scale; C, the emotional scale; D, the self-reported depression 
scale, i.e. the Children’s Depression Inventory (CDI). 
 
the 22 females who had been treated for psychotic disorders, 27.3% scored 
above the 90th percentile on the categorical emotional scale. In sex-stratified 
multivariate models including the two family variables and the four linear 
psychopathology scales, the conduct scale independently predicted treatment 
of psychotic disorders among males. 
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The results from univariate analyses of other specific diagnostic groups 
are summarized in Table 8. The multivariate models of specific diagnostic 
groups included the two family variables and the four linear psychopathology 
scales as predictors. In both sexes, treatment of mood disorders was 
independently predicted by the emotional scale and the self-reported 
depressive scale. Among males, treatment of anxiety disorders was 
independently predicted by the emotional scale. In both sexes, treatment of 
substance-related disorders was independently predicted by non-intact 
family structure and the conduct scale. The results regarding the 
psychopathology variables in the multivariate models of hospital treatment 
of psychotic, mood, anxiety, and substance-related disorders and other 
outcomes in the thesis are summarized in Figure 12.  
 
Figure 10 The prevalence of frequent bully-victim, frequent bully and frequent 
victim statuses at age 8 among females and males. 
5.3.4 BULLYING AND VICTIMIZATION AS PREDICTORS OF LATER 
PSYCHIATRIC TREATMENT (AIM 5; STUDY V) 
As shown in Figure 10, 6.4%, 6.0% and 2.8% of the males were classified as 
frequent victims (but not bullies), frequent bullies (but not victims), and 
frequent bully-victims, respectively. Among females, 3.6% were classified as 
frequent victims, while only 0.6% and 0.2% were classified as frequent 
bullies and frequent bully-victims, respectively (Figure 10).
In Figure 11, the univariate hazard ratios and 95% confidence intervals are 
shown for having psychotropic medication use and/or psychiatric hospital 
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Figure 11 Associations between frequent bully-victim (A), frequent bully (B) and 
frequent victim (C) statuses at age 8 and having psychotropic medication use 
and/or psychiatric hospital treatment between age 12 and 25. Hazard ratios (HR) 
and 95% confidence intervals (CI) are based on univariate Cox regression analysis. 
Children without frequent bullying or victimization were used as reference in the 
analyses. The association is significant at p<0.05 if the 95%CI of the HR does not 
include 1 (the dotted line). Summary of the figure in study V. 
 
treatment during the follow-up. Among males, the outcome was predicted in 
the univariate analyses by frequent bully-victim status (HR 3.8), frequent 
bully status (HR 1.6), and frequent victim status (HR 1.6) at age eight, when 
compared to males who were neither frequent bullies nor victims at age 
eight. When the total psychopathology score from the parent and teacher 
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reports was included as a covariate in the analysis, none of the bully or victim 
statuses predicted the outcome at a statistically significant level among males 
(p<0.05). Among females, the outcome in the univariate analyses was 
predicted by frequent bully status (HR 2.6) and frequent victim status (HR 
2.2) at age eight (Figure 11). Frequent victim status predicted the outcome 
even after adjustment with the total psychopathology score (HR 1.7, 95%CI 
1.1-2.5).  
The univariate results of frequent victim, frequent bully and frequent 
bully-victim status predicting antipsychotic, antidepressant, and hospital 
treatment of any psychiatric disorder are summarized in Table 8 (specific 
diagnoses were not analyzed due to the small number of subjects). When the 
total psychopathology score was included as a covariate in the analyses, no 
statistically significant associations could be found for antipsychotic use, 
antidepressant use, or PHT, among males. Among females, frequent victim 
status predicted antipsychotic use, antidepressant use, and PHT, when the 
total psychopathology score was included as a covariate in the analyses. 
5.3.5 SUMMARY OF UNIVARIATE RESULTS (AIMS 3 AND 5; STUDIES 
II-V) 
A summary of the univariate results of the family variables, the linear 
psychopathology scales, and the bullying and victim groups predicting 
antipsychotic use, antidepressant use, and hospital treatment of any 
psychiatric disorder, psychotic disorders, mood disorders, anxiety disorders 
and substance-related disorders are shown in Table 8. Altogether 99 analyses 
are described in Table 8, and of these, 49 associations (49.5%) reached a 
significance level lower than 0.05. 
Non-intact family structure predicted all outcomes in both sexes, except 
anxiety disorders in both sexes and psychotic disorders and mood disorders 
among females (Table 8). With regard to psychopathology scales, there were 
28 analyses per sex. Among males, 85.7% (n=24) of the tested 
psychopathology scales were statistically significantly associated with the 
studied outcomes, while the corresponding figure among females was 60.7% 
(n=17). Most notably, among males, the conduct scale predicted all 
outcomes. Also the hyperactivity scale predicted all outcomes, except mood 
disorders, among males. Among males, frequent bully-victim status 
predicted antipsychotic use, antidepressant use, and PHT, while frequent-
bully status predicted antidepressant use (specific diagnostic groups of PHT 
were not analyzed). Among females, the self-reported depressive scale 
predicted all outcomes, except hospital treatment of psychotic and 
substance-related disorders. Also the emotional scale predicted all outcomes, 
except treatment of anxiety and substance-related disorders, among females. 
Among females, frequent victim status predicted antipsychotic use, 
antidepressant use, and PHT, while frequent bully-victim and frequent bully 
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status did not predict these outcomes or were not analyzed due to the small 
number of subjects in these groups.  
 
5.3.6 SUMMARY OF MULTIVARIATE RESULTS OF 
PSYCHOPATHOLOGY VARIABLES (AIM 3; STUDIES II-IV) 
Figure 12 presents a summary of the independent associations of the 
psychopathology variables in predicting various outcomes. 
Definition of the models: The multivariate models did not include the 
same variables in studies II, III, and IV. Therefore, to compare the results, 
the multivariate models were re-analyzed including the same predictor 
variables in each model. The multivariate models in Figures 12A and 12B 
include family structure, parental education level, and the four linear 
psychopathology scales. The multivariate models in Figures 12C and 12D 
include family structure, parental education level, and the four categorical 
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Figure 12 Summary of Cox regression multivariate models. Each outcome was 
studied in a separate model. Multivariate models in A (males) and B (females) 
included the two family variables and the four linear psychopathology scales. 
Multivariate models in C (males) and D (females) included the two family variables 
and the four categorical psychopathology scales. Arrows indicate independent 
associations of psychopathology variables (associations of the family variables are 
not shown). 
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psychopathology scales. For descriptive purposes, the predictors are 
classified into variables that are mainly related to externalizing problems 
(black) or internalizing problems (light gray). The outcomes are depicted 
according to the childhood variables that are statistically associated: 
associated with externalizing problems (black), internalizing problems (light 
gray), or both externalizing and internalizing problems (medium gray).  
Results: The conduct scales independently predicted several outcomes 
among males (Figure 12A and 12C), but very few outcomes among females 
(Figure 12B and 12D). The emotional and self-reported depressive scale 
independently predicted mainly internalizing or mixed outcomes among 
both males (Figure 12A and 12C) and females (Figure 12B and 12D), but 
some differences were found: the self-reported depressive scale 
independently predicted antipsychotic use among females (Figure 12B and 
12D), but not among males (Figure 12A and 12C). The hyperactivity scale did 
not predict any of the studied outcomes independently in the multivariate 
analyses among males (Figure 12A and 12C), though the hyperactive scale 
predicted a wide range of outcomes in the univariate analyses (Table 8). 
Some methodological issues can also be seen. Since the number of subjects 
with each outcome differs, it is seen that the associations more easily reach a 
significant level if a large number of subjects are affected by the outcome. 
This is most obvious with the independent association seen for 
antidepressant use (230 males and 335 females) versus hospital treatment of 
mood disorders (37 males and 46 females): several highly significant 
associations are found for antidepressant use, whereas few associations are 
seen for treatment of mood disorders, though both outcomes deal with 
theoretically similar problems. It is also of note that the models including 
linear psychopathology scales (Figure 12A and 12B) show more statistically 
significant associations than the models including categorical 
psychopathology scales (Figure 12C and 12D). 
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6 DISCUSSION 
6.1 USE OF PSYCHOTROPIC MEDICATION (AIMS 1 AND 
2; STUDIES I AND II) 
6.1.1 CUMULATIVE INCIDENCE BY AGE 25 (AIM 1; STUDY I) 
The cumulative incidence of psychotropic medication use by age 25 was 
reported in this thesis, while most previous studies have reported one-year 
prevalence of psychotropic medication use. Therefore, the comparing of 
medication use in other studies is difficult. The cumulative incidence of any 
psychotropic medication use was 15% by age 25 in this study, while the one-
year prevalence of any psychotropic medication use in another Finnish 
register-based study was some 3% in the total age group 0-27 years in 2007 
(25). Antidepressants were used by 12% of the sample by age 25 in this study, 
which corresponds to another recently published Finnish register-based 
study of the total population (24). The one-year prevalence of antidepressant 
use in Finland was reported to be 5% among males and 8% among females 
aged 21-26 years in 2007 (25).  
In some previous studies of psychiatric disorders, lifetime prevalence or 
cumulative incidences have been reported. In a cross-sectional Finnish study 
from 2003-2005, which used diagnostic interviews and case records of 
psychiatric treatment, the lifetime prevalence of any axis I psychiatric 
disorder (i.e. personality disorders not included) was 40% among 19- to 35-
year-olds (224). Among those with a lifetime axis I disorder, according to self-
reports, 50% had been treated for mental health disorders at some point in 
the above-mentioned Finnish study (224). Hence, approximately 20% had 
been treated for mental disorders by age 35 in Finland (224). However, it is of 
note that in cohort studies which have used diagnostic assessment 
continuously throughout childhood, adolescence and young adulthood, the 
lifetime prevalence of disorders is doubled when compared to studies relying 
on retrospective measures and self-reports (157). For example, the lifetime 
prevalence of any mental disorder was 83% by age 21 in the Great Smoky 
Mountain study (61). In sum, there are great variations in design 
(retrospective/prospective) and in assessment of mental health treatment or 
psychotropic medication use. Therefore, no conclusions concerning how 
many with medication use actually had a diagnosable disorder, or how many 
with a lifetime disorder have used psychotropic medication can be drawn.  
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6.1.2 POLYPHARMACY USE (AIM 1; STUDY I) 
A total of 4% of the cohort had purchased two medications from different 
medication classes during the same day, which indicates polypharmacy use. 
Among youths who had psychotropic medication use, the proportion of 
polypharmacy use was 15% by the age of 20, and increased to 27% by the age 
of 25.  
The most common combination was the antidepressant-benzodiazepine 
combination, which had been used by 3% of the study population. Every 
fourth subject who had used antidepressants had used benzodiazepines 
concomitantly. Vice versa, the majority of the subjects who had used 
benzodiazepines had used them concomitantly with antidepressants. This 
common combination may be explained by the fact that mood and anxiety 
disorders are very often comorbid (128). It is also stated in treatment 
guidelines that benzodiazepines may be used in the acute phase of depression 
(19), and as a secondary treatment option after antidepressants in anxiety 
disorders (103). A preliminary observation from the TORDIA-study (the 
Treatment of SSRI-resistant Depression in Adolescents study) is that self-
harm behavior is more common among adolescents with treatment-resistant 
depression who are prescribed both antidepressants and benzodiazepines 
than among corresponding adolescents with antidepressants as monotherapy 
(39). Therefore, patients with this medication combination should be carefully 
followed up.   
Two out of three subjects, who had used antipsychotics, had used them 
together with antidepressants at some point. This combination has in 
previous studies been used in, e.g. psychotic depression, the treatment of 
comorbid depression and borderline personality disorder (245); fluoxetine-
olanzapine has been used in bipolar depression (226), antidepressants to 
reduce negative symptoms in schizophrenia (246), and to promote sleep in 
depression (242). 
6.1.3 TIMING OF THE FIRST PRESCRIPTION (AIM 1; STUDY I) 
Psychotropic medication use remained low before the age of 15, but increased 
substantially in late adolescence and young adulthood. There are several 
possible explanations for the increased medication use in late adolescence.  
1) Previous studies have shown that help-seeking because of psychiatric 
disorders is more common in late adolescence than in early adolescence (99, 
129). Help-seeking, again, in late adolescence may be common for a variety of 
reasons. Many life stressors, such as starting to work or study and moving 
away from home, co-occur with increased help-seeking in late adolescence. 
Furthermore, some psychiatric disorders, e.g. psychotic and substance-
related disorders, typically have their onset in late adolescence (179). However, 
the increase in depression incidence occurs already in early adolescence (127, 
  77
169). It is also worth noting that only a minority of adolescents with 
psychiatric problems use mental health services (99, 129, 213, 219).  
2) The indication of many psychotropic medications is only for the 
treatment of persons over 18 years of age. Therefore, it is possible that 
physicians prefer not to prescribe psychotropic medications for adolescents 
younger than 18 years old.  
3) Physicians might consider that the effectiveness of psychotropic 
medication is not as effective among adolescents as it is among young adults. 
Therefore, physicians might prescribe psychotropic medications for 
adolescents more seldom than for young adults. 
4) The peak of medication use incidence in late adolescence can possibly 
be explained by the mental health service system for adolescents versus 
adults. In another Finnish register-based study, among adolescents younger 
than 15 years, mainly specialized physicians (e.g. child and adolescent 
psychiatrists) prescribed antidepressants, while among older adolescents and 
young adults mainly non-specialized physicians prescribed antidepressants 
(24). On the basis of this background and the results in this thesis, it can be 
hypothesized that if a psychotropic medication is prescribed for a child or an 
adolescent, it is prescribed in some of the relatively few specialized units. On 
the other hand, if a psychotropic medication is prescribed for a young adult, 
it is prescribed in practically any service unit, e.g. health centers, 
occupational health centers, and private clinics. Further studies are needed 
to obtain more detailed information about pharmacological and non-
pharmacological treatment patterns of psychiatric disorders among 
adolescents versus young adults.  
6.1.4 PSYCHIATRIC HOSPITAL TREATMENT AMONG 
ANTIPSYCHOTIC USERS (AIM 2; STUDY II) 
Hospital treatment of psychiatric disorders is mostly used for severe 
disorders (37). Among antipsychotic users, three out of four had been treated 
in a hospital for a psychiatric disorder; every third had been treated for a 
non-affective psychotic disorder. Therefore, the results in this thesis indicate 
that antipsychotics are mostly prescribed for youth with severe psychiatric 
disorders in Finland. Similar results are found from a population-based 
study of 19-35-year-olds in Canada: 42% of antipsychotic users aged 19 to 35 
years had a schizophrenia diagnosis in 2006 (4). However, studies from some 
other countries have shown different patterns. Only one tenth of 
antipsychotic prescriptions by general practitioners were prescribed for non-
affective psychoses in a study of 10-99-year-olds in the UK (121). A study from 
the USA including all age groups reported that among antipsychotic users, 
19% had schizophrenia, 22% had an affective disorder, and 19% had an 
anxiety disorder according to self-reports in 2004-2005 (77). Studies of 
children and adolescents in the USA indicate that antipsychotics are mostly 
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prescribed for behavioral and affective disorders, while approximately every 
seventh antipsychotic prescription is for psychotic disorders (59, 170).  
The psychiatric diagnostic groups of hospital treatment differed among 
males and females with antipsychotic use. Among males with antipsychotic 
use, almost every second had been treated for a non-affective psychotic 
disorder, while one out of eight had been treated for an affective disorder. 
Among females with antipsychotic use, almost every second had been treated 
for affective disorders, while one out of four had been treated for non-
affective psychotic disorders. One explanation for this sex difference is that 
many non-affective psychoses are more common (181) and start earlier (240) 
among males, while affective disorders are more common among females (74). 
That is to say, the distribution of psychiatric disorders among males and 
females might explain the sex difference. 
6.2 CHILDHOOD PREDICTORS OF PSYCHIATRIC 
TREATMENT BY YOUNG ADULTHOOD (AIMS 3-5; 
STUDIES II-V) 
First, the predictors of each outcome are discussed. Second, the outcomes of 
each predictor are discussed from a broader perspective.  
6.2.1 PREDICTORS OF VARIOUS OUTCOMES (AIMS 3-5; STUDIES II-
V) 
6.2.1.1 Predictors of antipsychotic use (Aims 3 and 5; studies II and V) 
Externalizing problems, such as conduct and hyperactivity behaviors, at age 
eight predicted antipsychotic use among males. Among males who screened 
positive on the conduct scale at age eight, eight percent had used 
antipsychotics at follow-up, while only two percent of the screen-negative 
males had used antipsychotics. This is in line with prior studies that have 
shown that conduct problems predict psychotic disorders and several other 
psychiatric disorders (132). Some studies have reported that the association 
between childhood externalizing behavior and adult psychotic disorder is 
stronger among males than females (78, 174). 
Internalizing problems, such as anxiety and depressive symptoms, at age 
eight predicted later antipsychotic use among females. Females who screened 
positive on the self-reported depression scale had used antipsychotics three 
times more often than screen-negative subjects, while males’ reports of 
depressive symptoms did not predict the outcome. The sex interaction might 
partly be explained by the fact that antipsychotic medications were often 
prescribed for affective disorders, which are more common among females. 
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Furthermore, previous studies have shown that schizophreniform disorders 
in adulthood are associated with childhood internalizing disorders (132). Some 
studies suggest that childhood internalizing problems especially among 
females are associated with psychotic disorders in adulthood (78, 174). That is 
to say, different predictors of psychotic disorders among males versus 
females might also partly explain the sex interaction. 
Frequent bully-victim status predicted antipsychotic use among males, 
but the association did not remain statistically significant when adjusted with 
psychopathology scores. This indicates that antipsychotic use among males 
who are frequent bully-victims at age eight also have other types of 
externalizing problems, as described above. However, among females, 
frequent victim status predicted antipsychotic use also when adjusting for 
psychopathology scores at age eight (findings discussed in more detail in 
section 6.2.2.5).  
Living in a family with other than two biological parents was strongly 
associated with later antipsychotic use in both sexes (study II). This 
association may be explained by other risk factors, such as parental history of 
psychiatric disorder, family discord, child neglect and abuse (244), which are 
associated with living with other than two biological parents. 
6.2.1.2 Predictors of antidepressant use (Aims 3 and 5; studies III and 
V) 
Externalizing problems at age eight predicted antidepressant use among 
males, but the association was weak among females. In fact, the interaction 
between conduct problems and sex was significantly associated with 
antidepressant use. Previous studies have shown that childhood conduct 
problems predict adult antisocial personality disorder (167), but also adult 
internalizing problems, such as mood disorders and anxiety (86, 132, 167). 
However, some studies have found an association between childhood 
externalizing problems and adult internalizing problems only among males 
(2, 76, 244), while other studies have not found any sex differences (55, 86, 132, 194). 
The results in this thesis add to the literature by showing that childhood 
conduct problems predict later antidepressant use differently among males 
and females.  
Internalizing problems, measured by the self-reported depressive scale 
and the parent- and teacher-reported emotional scale, predicted 
antidepressant use in both sexes. This is in line with previous studies, which 
have reported a strong association between childhood emotional problems 
and similar adult problems (55, 132). A novel finding is that after adjusting for 
other psychopathology scores and other informant sources, the association 
between self-reports of depressive symptoms already at age eight and later 
antidepressant use remained significant. This result emphasizes the use of 
self-reports of depressive symptoms in middle childhood.  
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Both frequent bully-only and frequent bully-victim status predicted 
antidepressant use among males (study V). However, when adjusted with 
psychopathology scores, the association did not remain statistically 
significant. Among females, frequent victim status predicted antidepressant 
use in unadjusted and adjusted analyses of psychopathology scores at age 
eight (findings discussed in more detail in section 6.2.2.5).  
As in the study of predictors of antipsychotic use, living in a family with 
other than two biological parents at age eight independently predicted later 
antidepressant use. 
6.2.1.3 Predictors of antidepressant costs (Aim 4; study III) 
In this thesis, predictors at age eight of any lifetime antidepressant use 
(yes/no) were first studied. Then, when predictors of any antidepressant use 
were taken into account, lifetime antidepressant costs were studied. That is, 
predictors of both any antidepressant use and antidepressant costs were 
included in the same selection model. The major advantage of the selection 
model is that it can be tested whether the predictors of antidepressant costs 
are different than the predictors of any antidepressant use.  
Little evidence of predictors of antidepressant costs was found, when 
predictors of antidepressant use were taken into account. The only 
statistically significant result in the maximum likelihood (ML) outcome 
equation of lifetime antidepressant costs was that conduct problems at age 
eight were inversely associated with higher costs, when antidepressant use 
was taken into account. As noted above, young males with a history of 
childhood conduct problems are prescribed an antidepressant by age 25 
almost twice as often compared to males without childhood conduct 
problems. Conversely, once prescribed, the long-term costs might be lower 
due to early discontinuation of the antidepressant. Possible explanations for 
why males with a history of childhood conduct problems might discontinue 
antidepressant medication include, e.g. inappropriately assessed clinical 
diagnosis, unresponsiveness to the medication, and proneness to impulsivity.  
Nonetheless, the result that the conduct scale was inversely associated 
with antidepressant costs in the ML selection model should be interpreted 
with caution. First, though the finding was statistically significant, the 
standard errors in the outcome equation were large, indicating uncertainty. 
Second, the association was statistically significant in the final ML model, but 
not in the preliminary two-step model, although the estimates and standard 
errors were otherwise similar in the two models. Third, the proportion of 
zero costs was high, i.e. the level of censoring was high. A high level of 
censoring is common in health economic research (45), and it is one of the 
caveats of the selection models (44, 189). Despite these analytical challenges, 
the selection models were chosen as a primary analytic method and the 
models used in this thesis were well defined. In conclusion, the results 
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suggest that depressive symptoms at age eight do not predict antidepressant 
costs differently than antidepressant use. Externalizing symptoms at age 
eight as predictors of antidepressant use might operate differently as 
predictors of antidepressant costs. However, for definitive conclusions, the 
topic should be further studied in other samples. 
6.2.1.4 Predictors of psychiatric hospital treatment (Aims 3 and 5; 
studies IV and V) 
A wide range of predictors at age eight were associated with psychiatric 
hospital treatment (PHT). Among males, externalizing problems most 
strongly predicted hospital treatment for any psychiatric diagnosis. Among 
females, self-reported depressive symptoms at age eight had the strongest 
independent predictive association with PHT. These results are in line with 
previous studies showing that childhood psychopathology predicts intensive 
psychiatric treatment (78, 132, 238). 
The combination of conduct and emotional problems increased the risk of 
later PHT among both males and females more than the other studied 
psychopathology combinations at age eight. This group of children was small 
and consisted of approximately 4% of the total sample. Nonetheless, every 
fifth male and every eighth female, who had concurrent conduct and 
emotional problems at age eight, had been treated for a psychiatric disorder 
in a hospital by age 25. Previous population-based longitudinal studies have 
shown that childhood comorbid internalizing and externalizing problems 
among males are associated with substance use (82) and suicidality (82) in 
adulthood. In addition, it was shown in a previous report based on the 
military call-up data of the males in the current cohort, that comorbid 
conduct-emotional problems predict several psychiatric disorders in early 
adulthood (214). A new finding in this thesis is that comorbid externalizing 
and internalizing problems predict treatment for psychiatric disorders in 
both sexes, not only in males.  
Both frequent victim and frequent bully-victim status predicted PHT in 
both sexes. In addition, frequent bully-only status predicted PHT among 
males. However, when adjusting with psychopathology scores at age eight, 
only frequent victim status among females predicted PHT (findings discussed 
in more detail in section 6.2.2.5).  
6.2.1.5 Predictors of hospital treatment of psychosis and other 
diagnostic classes (Aim 3; study IV) 
Both externalizing and internalizing problems at age eight among males 
predicted hospital treatment of psychotic disorders. However, only conduct 
problems predicted treatment of psychotic disorder independently among 
males. Among females, parent- and teacher-reported emotional problems 
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predicted treatment of psychotic disorder in the univariate model. The term 
equifinality is often used to refer to the fact that a variety of problems in 
childhood can predict a specific disorder in adulthood (52). The results in this 
thesis are in line with the few studies which have reported sex-specific 
information on childhood psychopathology and later psychotic disorders (78, 
174). Most longitudinal population-based studies about childhood 
psychopathology and later psychotic disorders have not reported separate 
estimates for males and females (46, 116, 132, 214). However, other developmental 
sex differences than childhood psychopathology have also been found. For 
example, neurodevelopmental deficits are more severe among 
preschizophrenic males than females, and females have a later onset of 
schizophrenia symptoms than males (240).  
Hospital treatment of mood and anxiety disorders was predicted by 
similar problems in childhood in both sexes, which is in line with previous 
studies (132, 214). Conduct problems and non-intact family structure predicted 
treatment of substance-related disorders, in line with earlier studies (81, 214, 
239).  
6.2.2 OUTCOMES OF VARIOUS CHILDHOOD PREDICTORS (AIMS 3 
AND 5; STUDIES II-V) 
6.2.2.1 Externalizing problems (Aim 3: studies II-IV) 
Conduct problems at age eight independently predicted hospital treatment of 
substance-related disorders in both sexes, when other psychopathology 
variables were taken into account. Among males, conduct problems also 
independently predicted antipsychotic use, antidepressant use and hospital 
treatment for any psychiatric diagnosis and of psychotic disorders. The term 
multifinality has been used to describe how one characteristic predicts 
several different outcomes (52). The results in this thesis are in line with 
previous studies showing that conduct problems in childhood predict several 
different adverse outcomes in adulthood (132, 167, 205). Therefore, the results 
strengthen the view that early identification of children with conduct 
problems might provide an opportunity to prevent several adverse outcomes 
by offering these children targeted interventions (100). Novel findings in this 
thesis were that the predictive impact of childhood conduct problems on 
many outcomes in adulthood shows differences among males and females. 
Future studies are needed to replicate, e.g. why conduct problems predict 
antidepressant use strongly among males and weakly among females (54). 
Hyperactivity problems predicted several outcomes among males, when 
the hyperactivity scale was analyzed as a single predictor. However, when 
other psychopathology scales were included in the same models, the 
hyperactivity scale did not predict any of the studied outcomes 
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independently. This indicates that co-occurrence of hyperactivity problems 
and other psychopathological problems account for the majority of predictive 
associations described above. Some prior clinical (35) and population-based 
(194) studies have also shown that pure hyperactivity problems without any 
other types of comordid psychiatric problems do not have a strong impact on 
adult adverse outcomes.  
6.2.2.2 Internalizing problems (Aim 3; studies II-IV) 
The emotional scale and/or the self-reported depressive scale independently 
predicted antidepressant use and hospital treatment of any psychiatric 
diagnosis and mood disorders in both sexes. In addition, the scales 
independently predicted treatment of anxiety disorders among males and 
antipsychotic use among females. In sum, internalizing problems at age eight 
predicted outcomes that are mainly related to internalizing problems. The 
term homotypic continuity has been used to describe the finding that certain 
problems in childhood predict similar problems in adulthood (67). The results 
in this thesis are in line with previous studies, which have reported a strong 
association between childhood emotional problems and similar adult 
problems (55, 132). 
6.2.2.3 Comorbid externalizing and internalizing problems (Aim 3; 
study IV) 
The combination of externalizing and internalizing problems at age eight was 
studied with regard to one outcome, namely, hospital treatment of any 
psychiatric disorder. The combination of both externalizing and internalizing 
problems increased the risk of PHT six-fold among males and four-fold 
among females, while the “pure” externalizing and internalizing classes 
increased the risk three-fold among males and two-fold among females. The 
context of the findings has been discussed in more detail in section 6.2.1.4.  
6.2.2.4 Self- versus parent- and teacher-reported problems (Aim 3; 
studies II-IV) 
In studies II-IV, self-reported problems and parent- and teacher-reported 
problems were studied in parallel. Both reports by the children themselves 
and by the adults predicted several outcomes. Though agreement between 
informants is usually low, it is justified to use several informants, because 
different informants perceive different aspects of a child’s situation. 
However, little is known about the predictive value of self-reports in early 
school years, because other population-based cohorts with outcomes in 
adulthood have not included self-reports as early as age eight (214). 
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Novel findings in this thesis were that the self-reported depressive 
symptoms at age eight independently predict antidepressant use and hospital 
treatment of mood disorders in both sexes. The results indicate that adults 
do not necessarily notice depressive symptoms among eight-year-old boys 
and girls, although the children’s own report of depressive symptoms may be 
a marker for possible later internalizing disorders requiring hospital 
treatment or antidepressant medication. These findings have implications for 
early detection of children at risk. 
6.2.2.5 Bullying and victimization (Aim 5; study V) 
Bullying behavior, victimization of bullying behavior, and being both bullied 
and victimized predicted several outcomes. Males who were both bullied and 
victimized at age eight had the highest risk of several psychiatric outcomes. 
Females who were frequently victimized at age eight were at risk of a wide 
range of outcomes regardless of their psychiatric symptoms at age eight. 
There were two groups that included bullying behavior, namely, the 
frequent bully group and the frequent bully-victim group. The prevalence of 
frequent bully and of frequent bully-victim status at age eight was 6% and 
3%, respectively, among males, while it was only 0.6% and 0.2%, 
respectively, among females. That is, the overall rate of bullying was rather 
low, and bullying behavior was more common among males. In a study with 
data from 25 different countries, the prevalence of bullying varied between 
9% and 54% (163). An explanation for the lower prevalence rates in this thesis, 
is that study V included only frequent bullying and the children were eight 
years old at assessment, while the country comparison study included both 
occasional and frequent bullying and the samples consisted of students at 
average ages of 11.5, 13.5 and 15.5 years (163). The more strict definition of 
bullying in study V was justified by previous findings that frequent bullying 
substantially increases the risk of later psychiatric disorders among males, 
while occasional bullying increases the risk at most moderately (197). The 
finding that bullying was more common among males is in line with previous 
findings showing that males have higher levels of aggression and impulsivity 
(22, 50, 68). 
Every second male who was a frequent bully-victim at age eight had 
undergone either psychotropic medication treatment or hospital treatment of 
a psychiatric disorder by age 25. This is in line with previous findings 
indicating that males who are both bullies and victims have the poorest long-
term prognosis (118, 216). Being a frequent bully, but not a victim, also 
increased the risk of psychiatric treatment in adulthood, but to a smaller 
extent than being both a bully and a victim. However, psychiatric symptoms 
among frequent bully-victims and frequent bullies explained the association 
with later psychiatric outcomes. Among the few females who were frequent 
bullies at age eight, the risk of psychiatric treatment by age 25 was also 
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increased. The small number of subjects in this group warrants caution in 
interpreting this result. Previous studies have used the term “gender-
paradox” to describe the fact that antisocial or bullying behavior is 
uncommon among females, but when such behavior is present among 
females, the impairment is worse than among corresponding males (43, 147). 
The implication of these findings is that both males and females who present 
bullying behavior should be evaluated for psychiatric symptoms, because the 
combination of bullying behavior and psychiatric symptoms can be a marker 
of psychiatric long-term outcomes.  
The prevalence of being a frequent victim of bullying behavior at age eight 
was 6% among males, and 4% among females. Females who were victims of 
bullying behavior at age eight were at risk of several psychiatric outcomes by 
age 25, regardless of the level of psychiatric symptoms at age eight. Males 
who were victims at age eight were at modest risk of some psychiatric 
outcomes, but the predictive association was explained by the psychiatric 
symptoms at age eight. These results are in line with previous cross-sectional 
and short-term follow-up studies showing that victimization is associated 
with psychiatric outcomes especially among females (23, 38, 130, 134). 
One explanation for why victimization is associated with later psychiatric 
treatment more strongly among females than among males is that the type of 
bullying and victimization among females is different from that among 
males. Relational forms of victimization, such as being a victim of social 
exclusion and gossip, are more common among females than males (70-72, 176). 
Among males again, physical victimization is more common (70, 72). A 
previous cross-sectional study showed that indirect forms of victimization, 
such as being excluded and ignored, were more strongly associated with 
depressive symptoms than direct forms of victimization, such as being hit 
and kicked (233). Therefore, it is possible that females have experienced 
psychologically more traumatic forms of victimization than males. A further 
possible explanation is that adults might more easily notice physical 
victimization among boys than relational forms of victimization among girls. 
If adults notice victimization and interfere at an early point, it is possible that 
the victimization does not continue for a long time and the long-term 
prognosis is better.  
6.2.2.6 Family characteristics (Aim 3; studies II-IV) 
In line with several other studies, living with other than two biological 
parents predicted a wide range of outcomes (85, 239). However, a non-intact 
family should not be seen as a risk per se. There are several problems 
associated with both intact family structure and psychiatric outcomes among 
offspring, such as psychiatric problems among parents, disadvantageous 
child-rearing practices, financial problems, family violence, and weak 
parental support (85, 244). Lower parental education level than completed 
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upper-secondary school showed very few associations with the studied 
outcomes. It is possible that more specific measures of the parents’ 
education, cognitive abilities, work, or salary would have shown associations 
with the studied outcomes. Unfortunately, more specific family 
characteristics were not assessed in this cohort.  
6.3 METHODOLOGICAL CONSIDERATIONS 
The strengths and limitations of the thesis are summarized in Table 9. First, 
the general design issues of the cohort are listed, such as the nationwide 
design. Second, the baseline methodological issues are inspected. Third, the 
methods at follow-up are shown, that is, the methodological issues related to 
register-based research.  
In summary, the major strengths of the cohort used in this thesis include 
the representativeness of the source population, the nationwide design, the 
large sample size, the use of several informants at age eight, and the use of 
reliable nationwide registers at follow-up to assess psychotropic medication 
use and hospital treatment. The use of registers made it possible to track all 
the subjects with a correctly documented personal identification code. 
Therefore, the attrition was small and due to random error. Furthermore, the 
registers used in the thesis are very reliable with regard to the timing of the 
hospital treatment and the purchase date of the medications. The major 
limitations of the thesis are the use of only one baseline assessment, the lack 
of information about childhood psychiatric diagnoses, the lack of more 
specific information about the family, and limitations related to register-
based research. The registers are developed and maintained for 
administrative purposes and not primarily for research purposes. Therefore, 
information that could be of interest from a research point of view, such as 
indications of medications, is not necessarily recorded in the registers. 
Furthermore, register-based research cannot assess certain outcomes, which 
can only be studied if the study subjects are contacted. Such outcomes 
include, e.g. psychiatric symptoms in the population and whether the 
subjects actually continue to use the medication after the purchase. However, 
based on the finding that the majority of psychotropic medication users and 
80% of antidepressant users purchase the medication twice or more often, it 
is indicated that the medication is actually used.  
In comparison with other population-based cohorts from childhood to 
adulthood (reviewed in section 2.2.2), the cohort used in this thesis has 
general strengths to study predictors of certain service use patterns. These 
strengths are mainly related to the large, nationwide, representative sample, 
the use of nationwide registers, and the linkage procedure with unique 
personal identification codes. For example, the purchase date of the first 
antidepressant and the subsequent cumulative costs of antidepressants 
cannot be reliably assessed using questionnaires or interviews. In other 
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studies where service use is assessed with questionnaires or interviews, the 
timing and cumulative costs of specific forms of service use are hard to assess 
reliably. However, such studies have the strength to assess a wide range of 
service use forms, e.g. primary care, private physicians, and social services 
(64).  
 
Table 9   Summary of strengths and limitations by methodological issues. 
Methodological 
issue 
Strengths Limitations 
General design   
Nationwide cohort Few child psychiatric population-based 
cohorts are nationwide. 
Such nationwide studies have not 
previously been linked to nationwide 
registers, making high follow-up rates 
possible. 
It was possible to calculate the 
incidence of medication use with the 
cohort design (study I; most other 
studies have reported 1-year 
prevalence). 
Some personal identification 
numbers were lost or 
incorrectly documented.  
Sample size A unique sample size making it 
possible to, e.g.,  
- study males and females separately, 
- study interactions, and  
- study rare events, such as psychotic 
disorders. 
The sample size was 
relatively small for some rare 
outcomes. 
Age-homogenous 
cohort 
A cohort of children born in the same 
year was chosen, so the whole 
spectrum of disorders could be 
addressed; also the disorders occurring 
more seldom. 
The age effect of increased 
psychotropic medication use 
in late adolescence could not 
be ruled out by the period 
effect, i.e. that the increase 
was due to an increase in 
psychotropic medication use 
during those years. 
However, no sudden 
increases of psychotropic 
medication use among 
young people can be found 
between 1997 and 2005, 
according to another Finnish 
study (ref. 25). 
Methods at 
baseline 
  
Questionnaires The standardized brief questionnaires 
could be administered in a classroom 
setting and by sending the 
questionnaires to the parents: 
- three different informants 
- obtain a large sample size at relatively 
low cost 
Lack of more specific 
information such as 
psychiatric diagnoses. 
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Table 9 continued   (methods at baseline and follow-up) 
Methodological 
issue 
Strengths Limitations 
Methods at 
baseline 
  
Bullying/victimization 
questions 
The same questions to all three 
informants. 
Possible to combine information about 
a strict definition of 
bullying/victimization (bullies/is bullied 
frequently according to at least one 
informant versus never or sometime 
bullies/is bullied).  
Lack of more specific 
information about 
bullying/victimization: 
- bullying executed by 
males or females 
- physical aggression, 
verbal aggression or social 
exclusion 
Family variables The study includes information about 
family structure. 
Lack of information about 
more specific family 
characteristics and events 
in the family environment, 
such as rearing practices, 
weakened parent support, 
parent-child discord, 
maltreatment, family 
violence, financial problems 
and psychiatric problems 
among parents. 
Assessment once at 
age 8 
Includes self-reports already at age 8, 
which is earlier than in prior 
population-based studies from 
childhood to adulthood. 
With one “snap-shot” of 
childhood problems, the 
study lacks information to 
specify whether the 
problems were present 
once or if the problems 
continued for a longer time. 
Methods at follow-
up 
  
The use of 
nationwide registers 
Possible to link the nationwide sample 
and to obtain a low attrition rate. The 
attrition was due to random error, 
such as incorrectly recorded 
identification numbers. 
Not possible for the 
researcher to affect what 
kind of information is 
gathered in the registers. 
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Table 9 continued   (methods at follow-up) 
Methodological 
issue 
Strengths Limitations 
Methods at 
follow-up 
  
Nationwide 
prescription 
register 
- Nationwide reliable information about 
the used medication, the date of the 
purchase and the cost of the 
medication. 
- At the time of the study, the 
register lacked information 
e.g. about the indication of 
the medication or the 
prescriber  
- The register was 
established in 1994, when 
the subjects were 12-13 
years old. However, the use 
of psychotropic medication 
under that age has been 
very low and it is thus 
unlikely that the lifetime 
prevalence estimates are 
affected.  
- Lack of information on 
whether the subjects actually 
used the medication. 
However, the clear majority 
of users made at least two 
purchases, which indicates 
actual use. 
Finnish hospital 
discharge register 
- Nationwide reliable information about 
the diagnosis that was set during the 
inpatient treatment, and about the date 
of the admission. 
- According to previous studies, the 
diagnostic validity of psychotic 
disorders in Finnish inpatient treatment 
is good among adults. 
- Lack of information about 
the diagnostic validity of e.g. 
anxiety disorders. 
- Only minority of subjects 
with psychiatric disorders 
end up in hospital treatment, 
except subjects with 
schizophrenia and other 
psychotic disorders. 
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7 CONCLUSIONS 
7.1 MAIN FINDINGS 
The finding that 15% of the study population had used any psychotropic 
medication and 12% had used antidepressants by age 25 extends previous 
findings indicating that psychotropic medication use is common among 
young adults. However, previous studies have mainly reported psychotropic 
medication use during one year. Therefore, this thesis extends previous 
findings of one-year prevalence by assessing psychotropic medication use 
prospectively from early adolescence to young adulthood.  
The other main finding is that childhood mental health problems predict 
certain types of psychiatric treatment in adulthood differently among males 
and females. For example, conduct problems predict antidepressant use 
more strongly among males than among females; self-reported depressive 
symptoms predict antipsychotic use among females, but not among males; 
and being a victim of bullying predict psychotropic medication use and PHT 
among females, regardless of other childhood psychiatric problems, while 
among males, victimization shows only modest associations with the same 
outcome. 
7.2 IMPLICATIONS FOR PUBLIC HEALTH AND 
CLINICAL PRACTICE 
The results in this thesis and in several other studies show that a diversity of 
mental health problems in middle childhood is associated with psychiatric 
treatment in adulthood. Short-term treatment trials have shown that many of 
these childhood mental health problems can be treated effectively (195). This 
suggests that intervening in children at risk can reduce psychiatric problems 
during a short follow-up. Whether these effects can be extended into adult 
life is not certain, because there are no long-term follow-up studies of 
preventive interventions of childhood mental health problems (165). However, 
other types of childhood intervention studies have shown promising long-
term results (101, 102). For example, in a study of 3-4-year-old African-
American disadvantaged children, the intervention consisted of morning 
programs at schools and home visits by a teacher (102). At follow-up at age 40, 
the intervention group had higher rates of school graduation, higher salaries, 
less welfare assistance, and fewer arrests than the control group (102). 
Therefore, it is likely that prevention of mental health problems in childhood 
also has long-term effects.  
If the screening for prevention is systematic, it is important to remember 
that there are a number of screening criteria to be fulfilled (165). Some of these 
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criteria are fulfilled in accordance with current knowledge; for example, the 
preventable conditions are important health problems (65, 162, 205). However, 
the possible stigmatization, the potential of labeling, and the extra workload 
(165) in schools, primary care, and specialized care remain important 
questions if universal screening for prevention is applied. 
In Finland, school health care includes health check-ups throughout 
primary school (age 7-15) (210). These routine check-ups are performed by 
public health nurses and physicians and focus on physical health, mental 
health, and the well-being of the family (210). However, these check-ups, 
which sometime include questionnaires concerning psychiatric symptoms, 
are not named under the national screening programs (screening for breast 
cancer, cervix cancer and fetal chromosome and growth defects during 
pregnancy) (154). Thereby, the assessment of mental health problems among 
school-aged children is not completely systematic, but should be performed 
routinely according to the government decree from 2009 (210). The findings in 
this thesis have implications for these health care check-ups in schools, but 
also in primary care, and specialized care. Several psychiatric treatment 
forms in adulthood were predicted differently among males and females. 
These findings highlight the need to consider mental health problems sex-
specifically when evaluating the prognosis of mental health problems in early 
school years.  
7.3 IMPLICATIONS FOR FUTURE RESEARCH 
The lifetime use of psychotropic medication and the age of onset of 
psychotropic medication treatment should be further studied in other 
countries, because currently most studies have reported one-year prevalence 
of medication use. One important tool that could be used to study these 
pharmacoepidemiological issues are the Nordic prescription registers (5, 93).  
The general problem with observational longitudinal studies is that it is 
difficult to draw certain conclusions of causality. Researchers aim to 
minimize the problem by checking for potential confounders, which could 
explain the association. A limitation of this thesis is that it includes childhood 
characteristics from only one time-point, and it might have missed important 
confounders. The sex-specific findings in this thesis should be further 
analyzed in other population-based studies. For example, are the predictive 
associations among males and females explained by variations in genetic 
background, prenatal factors, or coping strategies of problems in the family? 
The study of sex-related issues is important, because they can contribute to 
the understanding of causal mechanisms involved in the development of 
psychopathology (201). Furthermore, would the positive predictive value of the 
studied outcomes be higher if information on predictors from other age 
periods were combined with the currently used information? For example, 
would it be more achievable to include information on early childhood 
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development and mental health problems in both childhood and adolescence 
when studying adverse outcomes in adulthood? These issues would be of 
importance when studying at what age or at what combinations of age 
periods possible screening should be performed. 
The outcome in this study was related to treatment of mental health 
problems in adolescence and young adulthood. It is possible that the positive 
predictive value would have been higher if the outcome had also included 
untreated cases of mental health problems. Therefore, the sex-specific 
findings need replication using other outcomes, such as questionnaire or 
interview-based information on mental health problems. From a more 
general point of view when considering screening, other outcomes are also of 
interest, such as unemployment, social exclusion, and criminal offences.  
Finally, as noted above, there are mainly short-term follow-up studies of 
preventive interventions. Therefore, there is an urgent need for long-term 
follow-up studies on how much screening and prevention of childhood 
mental health problems can reduce similar problems in adulthood. When 
conducting these studies, the cost-effectiveness of the interventions should 
also be taken into consideration.  
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